OPTIMIZING HER2 ANTIGEN PRESENTATION IN THE MHC I by Sippel, Trisha Rene
Northern Michigan University
NMU Commons
All NMU Master's Theses Student Works
2009
OPTIMIZING HER2 ANTIGEN
PRESENTATION IN THE MHC I
Trisha Rene Sippel
Northern Michigan University
Follow this and additional works at: https://commons.nmu.edu/theses
This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been accepted for inclusion in All NMU
Master's Theses by an authorized administrator of NMU Commons. For more information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.
Recommended Citation
Sippel, Trisha Rene, "OPTIMIZING HER2 ANTIGEN PRESENTATION IN THE MHC I" (2009). All NMU Master's Theses. 507.
https://commons.nmu.edu/theses/507
 
 
 
 
OPTIMIZING HER2 ANTIGEN PRESENTATION IN THE MHC I 
 
By 
 
Trisha Rene Sippel 
 
 
 
 
 
 
 
 
 
THESIS 
 
Submitted to 
Northern Michigan University 
In partial fulfillment of the requirements 
For the degree of 
 
MASTERS OF SCIENCE 
 
Graduate Studies Office 
 
2009 
SIGNATURE APPROVAL FORM 
 
 
 
 
 
 
 
This thesis by Trisha Rene Sippel is recommended for approval by the student’s 
thesis committee in the Department of Biology and by the Dean of Graduate 
Studies. 
 
 
 
Committee Chair:  Dr. Robert Winn             Date 
 
 
 
 
First Reader:  Dr. John Rebers          Date 
 
 
 
 
Second Reader:  Dr. Richard Rovin         Date 
 
 
 
 
Department Head:  Dr. Robert Winn          Date 
 
 
 
 
 
 
 
 
Dean of Graduate Studies:  Dr. Cynthia Prosen       Date 
OLSON LIBRARY 
NORTHERN MICHIGAN UNIVERSITY 
 
 
 
THESIS DATA FORM 
 
 
 
In order to catalog your thesis properly and enter a record in the OCLC 
international bibliographic data base, Olson Library must have the following 
requested information to distinguish you from others with the same or similar 
names and to provide appropriate subject access for other researchers. 
 
 
 
 
Trisha R. Sippel  5/17/85
i 
 
ABSTRACT 
 
OPTIMIZING HER2 ANTIGEN PRESENTATION IN THE MHC I 
 
By 
 
Trisha R. Sippel 
 
 HER2 is overexpressed in some breast cancers, leading to an aggressive form of 
the disease.  Recent research has targeted HER2 overexpressing tumor cells through the 
activation of cytotoxic T cells.  To do this, HER2 antigens must be cross-presented from 
the extracellular environment into the MHC I.  To measure cross-presentation, a 
variation of HER2 (EVI) which contains the sequence SIINFEKL was presented to 
splenocytes.  If the splenocytes present SIINFKEL in the MHC I, they will activate the 
cytotoxic T cell line (B3Z), which is specific to SIINFEKL presented in the MHC I.  In 
attempt to increase cross-presentation, EVI was glycosylated by conjugation to oxidized 
mannan.  The glycosylated EVI demonstrated an increased cytotoxic T cells response 
when compared to the non-glycosylated EVI, as measured by activation of B3Z cells 
through production of β-galactosidase.  The β-galactosidase production was also greater 
than that seen in response to the SIINFEKL peptide itself.  In another attempt to increase 
cross-presentation of whole protein, antigens were mixed with commercial transfection 
agents.  The transfection agent PULSin was able to increase β-galactosidase production 
in response to ovalbumin.  This result indicates that transfection agents may be useful 
for increasing cross-presentation.  This study provides insights into the optimal antigenic 
conditions to consider when creating a tumor vaccine against HER2.  
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LITERATURE REVIEW 
 
Human Epidermal Growth Factor Receptor 2 (HER2) is a protein receptor found 
on most cells in the body (Bernhard et al., 2002).  It facilitates the regulation of cell 
growth and proliferation through interactions with its HER family members.  When 
overexpressed on the cell surface, the cell can become hyper-sensitive to growth 
factors, or the receptor may become activated without binding a growth factor, causing 
the cell to grow and divide out of control (Moasser, 2007a).  This overexpression of 
HER2 has been shown to be the cause of 25-30% of all breast cancers  
(Slamon et al., 2001).  Because HER2 is a self-protein, these cancer cells then go 
unrecognized by the immune system, making HER2 overexpressing breast cancer an 
aggressive form of the disease.  The presence of HER2 overexpression has been 
correlated with decreased survival and a faster progression of the disease when 
compared to those with breast cancer not overexpressing HER2 (Slamon et al., 2001).  
For this reason, HER2 has become a molecular target for breast cancer therapy.   
In its natural form, HER2 belongs to a family of four epidermal growth factor 
receptors: epidermal growth factor receptor (EGFR, HER1, erbB1), HER2  
(erbB2, HER2/neu), HER3 (erbB3), and HER4 (erbB4).  The HER family proteins are 
transmembrane tyrosine kinase receptors which upon binding of a ligand to the 
extracellular domain will undergo either heterodimerization with one of the other HER 
family proteins or homodimerization with its equivalent HER family protein.  This 
dimerization induces transphosphorylation of the intracellular domain, activating the 
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receptor (Moasser, 2007a).  Signaling molecules are subsequently able to bind the 
phosphorylated tyrosine residues, activating downstream second messenger pathways 
such as MAP kinase and PI3K/Akt.  Both help signal the cell for proliferation and survival 
(Hudis, 2007).  Akt especially is involved with many pathways, acting as an initiator for 
several different signals that regulate cellular functions important for the formation of 
cancer cells.  Some of these functions include epithelial-mesenchymal transition, 
invasiveness, genome stability, cell cycle control, and angiogenesis  
(Moasser, 2007a). 
Of the HER family, HER2 has the strongest catalytic kinase activity, giving it the 
strongest signaling capability when dimerized with other HER family proteins.  Unlike 
the other HER family proteins, HER2 does not contain a ligand binding domain.  As a 
result, its extracellular domain does not switch between an active and inactive 
conformation, but instead exists in a constitutively activated conformation.  When the 
HER2 gene becomes overexpressed, the amplification of the receptor on the cell surface 
can cause HER2 to form homodimers, which do not usually occur under normal 
expression (Garret et al., 2003).   With its constitutively active conformation and strong 
signaling ability, overexpression of HER2 leads to increased stimulation of its signaling 
pathways, resulting in uncontrolled cell proliferation and survival. 
The overexpression of the HER2 protein can occur either through amplification 
of the gene itself, or through deregulation of transcription within the cell  
(Slamon et al., 1989).  Breast cancer tumors have been found to contain anywhere from 
25 to 50 copies of the HER2 gene per cell, causing a 40-100 fold increase in HER2 protein 
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expression and resulting in up to 2 million receptors on the cancer cell surface.  When 
HER2 is overexpressed on a cancer cell, the overabundance of growth signaling, along 
with subsequent evasion of signaling control, is usually the initial cause of the cancer.  
HER2 amplification is also maintained throughout disease progression and metastasis.  
Therefore, HER2 amplification is a subtype of breast cancer, rather than an indication of 
a later stage (Moasser, 2007a).   
 Initially it was proposed that a mutation in the HER2 gene could form a mutated 
HER2 protein that would then be constitutively activated, causing continuous 
downstream signaling of proliferation without dimerization.  Using rodent models, it has 
been demonstrated that a single base pair mutation causes a truncated version of the 
HER2 protein that is missing the extracellular domain and is constitutively active.  This 
mutation has not been found in humans.  It has been predicted that the human form of 
the protein would require a two base pair substitution, which is much less likely to occur 
than a single base pair mutation (Moasser, 2007b). 
 Just as HER2 is responsible for the initiation of tumorgenesis, it is also required 
for the continuation of tumor growth.  This dependency of the tumor on HER2 
expression has been termed ‘oncogene addiction’.  Without the overexpression of 
HER2, the tumor cells would no longer grow out of control.  Cell culture experiments 
have demonstrated that the knockout of HER2 by siRNA in cancer cell lines 
overexpressing HER2 results in cell death.  Tumors not overexpressing HER2 however 
are not responsive to HER2 knockdown (Moasser, 2007a). 
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 A better understanding of HER2’s transforming ability and aptitude to maintain 
tumor proliferation has come with the study of cancer stem cells.  These cancer stem 
cells express properties similar to normal stem cells in that they are able to self renew 
and also differentiate into specific cell types.  They are therefore thought to be the 
tumor-initiating cells, driving the uncontrolled growth of the tumor by deregulating their 
self-renewal pathways.  Korkaya et al. (2008) demonstrated that HER2 amplification 
regulates the mammary stem/progenitor cell population to drive tumorgenesis.   They 
showed that HER2 overexpression on both normal mammary epithelial cells and 
malignant mammary cells causes an increase in the stem/progenitor cell population as 
identified by the stem cell marker aldehyde dehydrogenase (Korkaya et al., 2008).   
As a result of HER2 overexpression driving tumorgenesis and invasiveness, and 
the tumor’s dependence on it for survival, HER2 is an excellent target for breast cancer 
therapy.  One successful approach at targeting HER2 was the use of the monoclonal 
antibody trastuzumab.  Trastuzumab, a humanized mouse monoclonal antibody, is 
derived from the combination of a murine antigen binding domain specific to HER2 with 
the framework region of human IgG (Carter et al., 1992).  A phase III clinical trial of the 
monoclonal antibody in combination with the standard chemotherapy treatment for 
breast cancer correlated to a longer time to disease progression, higher rate of objective 
response, longer duration of response, and lower death rate at one year.   
Women who had relapsed after chemotherapy also had a greater response when 
a different chemotherapy was combined with trastuzumab compared to the new 
chemotherapy alone.  In addition, women who had significantly greater amplification of 
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HER2 benefited more from the addition of trastuzumab to their chemotherapy 
treatment when compared to women who had HER2 overexpression to a lesser extent, 
indicating the specificity of trastuzumab to inhibiting HER2 activity (Slamon et al, 2001).  
After this phase III trial, Trastuzumab (more commonly known as Herceptin) was 
approved by the FDA for treatment of HER2 breast cancer and is now considered a 
standard therapy. 
The side effect of trastuzumab treatment of greatest concern, especially in 
combination with anthracycline chemotherapy treatment, is cardiac dysfunction.  
Several other side effects were observed during the phase III trial; however, none were 
severe enough to cause the discontinuation of treatment.  Cardiac dysfunction, on the 
other hand, was the cause of discontinuation for eight percent of the participants 
(Slamon et al., 2001).  A larger study indicated the risk of cardiotoxicity to be 4.7% in 
patients receiving trastuzumab (Eisenhauer, 2001).  Evidence suggests that cardiac 
dysfunction, as a result of trastuzumab treatment, occurs from the presence of HER2 
receptors or a related cross-reactive antigen on cardiac muscle.  When patients with 
HER2 positive breast cancer were treated with radiolabeled trastuzumab, myocardial 
uptake was observed, followed by subsequent cardiotoxicity.  The antibody therefore 
was not only targeting the tumor cells, but also the myocardium (Behr, 2001). 
 In order to make the treatment more effective and avoid the side effect of 
cardiac dysfunction, it is important to understand the mechanism behind which 
trastuzumab acts on HER2.  Several different mechanisms of action have been predicted 
for trastuzumab.  When the antibody binds the extracellular domain of HER2, it may 
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block dimerization of HER2 with any of the other HER receptors. It could also cause an 
increase in the endocytotic destruction of the receptor, or prevent shedding of the 
extracellular domain of HER2.  Shedding of the extracellular domain has been linked to 
autophosphorylation of the intracellular domain and therefore activation of the 
secondary messenger pathways.  It has also been suggested that binding of the antibody 
to the receptor could induce the activation of cell mediated cytotoxicity which would 
then lead to destruction of the cancer cell by immune effector cells (Hudis, 2007).    
Understanding the mechanism by which trastuzumab works may also help 
develop additional strategies for targeting HER2, especially for HER2 overexpressing 
tumors that are resistant to trastuzumab.  While trastuzumab has proved to have a 
significant impact on treatment of HER2 overexpressing breast cancer, a relatively large 
fraction of patients treated with adjuvant chemotherapy still relapse, one-third of 
patients with advanced forms of the disease fail to respond, and the majority of initial 
responders have disease progression within one year (Korkaya et al., 2008).  In order to 
increase the benefit of HER2 therapy, other methods of targeting the molecule are 
being developed.  
One area of focus involves the final proposed mechanism of action for 
trastuzumab involving an immune effector response.  Instead of using a monoclonal 
antibody to target the receptor for immune destruction, attempts have been made to 
develop a vaccine against HER2 through presentation of the protein to antigen 
presenting cells.  Not only would this method possibly target HER2 cancer cells, but it 
might also create an immunological memory that could prevent relapse after the initial 
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therapy.  It would have the advantage of creating an immune response to a protein 
already present in the body, but only target those cells that overexpress the protein, not 
those that have the protein at basal levels (Bernhard et al., 2002).   
When creating a vaccine against a self-protein, such as HER2, there is concern 
that an immune response will not be mounted against the antigen because the T cells 
specific to the antigen presented in the vaccine would already be eliminated to avoid 
self-reactivity.  It was observed that patients with HER2 overexpression naturally have a 
pre-existing immune response to HER2, both in the form of antibodies and T-cell 
immunity, showing that not all T cells specific to HER2 have been eliminated, and 
making it a possible candidate for use in a vaccine.  The immune response was found 
only in patients who had overexpression of HER2, and was of very low magnitude 
(Bernhard et al., 2001).  This pre-existing response showed no evidence of autoimmune 
disease, indicating the immune response did not attack cells with basal expression of 
HER2, and further supporting the development of vaccines in attempt to boost the 
immunity of these patients. 
 Normally, to avoid self-reactivity, when a self-protein is processed there are 
certain dominant antigens that are presented due to the breakdown of the protein and 
combination of the peptide fragments with major histocompatibility complexes (MHCs).  
These dominant antigens prevent activation of the immune system against the self-
protein.  When the protein is overexpressed however, there is more protein to be 
processed by antigen presenting cells and other, less dominant, peptide fragments 
besides the dominant antigens are able to be presented.  These other fragments can 
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then induce an immune response against the protein.  This mechanism can be mimicked 
through a vaccination that presents large amounts of protein to antigen presenting cells 
to be processed (Bernhard et al., 2002).  Since the tumor is overexpressing the protein 
as well, the vaccine will specifically target the other, less dominant, fragments 
presented on the tumor cell and not the dominant self antigens on normal cells.   
Early results from previous vaccine attempts have shown that immunity could 
not only be elicited, but remain intact after vaccinations had ended.  These kinds of 
vaccines may not only be used as a therapeutic agent for patients with HER2 
overexpressing breast cancer, but may also to prevent remission or even the onset of 
breast cancer (Bernhard et al., 2002).  This suggests that the severe risk of cardiac 
dysfunction related to treatment with trastuzumab could be eliminated through the use 
of vaccines and that these vaccines could be used in conjunction with standard therapy 
for an increased benefit.   
 Rohrbach et al. (2005) produced a vaccine in attempt to target delivery of the 
HER2 (ErbB2) protein to professional antigen presenting cells (APCs).  The vaccine 
antigen was formed by producing a chimeric protein containing an ErbB2 fragment with 
the extracellular domain of cytotoxic T-lymphocyte antigen-4 (CTLA-4).  CTLA-4 is 
normally found on T cells and specifically binds to B7 molecules on the APC surface, 
aiding in internalization of the peptide.  This protein was named C-ErbB2 and produced 
through bacterial expression.  Another variation of C-ErbB2 was engineered to also 
contain the Pseudomonas exotoxin A translocation domain, which acts as a cytotoxin to 
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cause cell death (C-E-ErbB2).  These two vaccines were then compared to recombinant 
ErbB2 (ErbB2222) as a control (Rohrbach et al., 2005). 
The chimeric proteins were able to bind strongly to the antigen presenting cells 
and were internalized rather quickly (the C-ErbB2 within one hour), which is an essential 
step for the generation of peptide epitopes and antigen presentation.  When these 
peptides were injected into mice as a vaccine, the mice were able to reject tumor 
formation when challenged with ErbB2 tumor cells as compared to mice vaccinated with 
only PBS.  Not only were they able to ward off tumors, but when re-challenged with the 
tumor cells two months after vaccination the mice that received the C-ErbB2 were still 
immune to tumor formation (Rohrbach et al., 2005). 
This study also showed that tumor rejection was dependent on induction of CD8+ 
effector cells by the protein vaccination.  Mice were vaccinated with either C-ErbB2 or 
C-E-ErbB2 and then injected with CD8- and/or CD4-specific antibodies to deplete these T 
cell populations.  When challenged with the tumor cell inoculation, tumors grew in the 
mice with depleted CD8+ or CD8+ and CD4+ effector cells to an extent comparable to 
mice vaccinated with only PBS.  The mice with only depleted CD4+ cells however were 
still able to reject tumor formation (Rohrback et al., 2005).  This showed that the CD8+ 
cells were required for tumor rejection.  It also suggested that the antigen delivered to 
the APC was loaded into MHC I, since CD8+ T cells recognize antigens presented only in 
MHC I. 
Two important aspects of this study were the discovery that HER2 could be 
presented to antigen presenting cells and used to form an immune response against 
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tumor cells overexpressing HER2, and that the antigen was being presented primarily 
through MHC I, which targeted CD8+ T cells.  This suggests that if the antigen could be 
altered in another way to provide better uptake and presentation by the APCs, it could 
have an even greater effect on targeting HER2 tumors.  One possible alteration would 
be the addition of glycosylated subunits to the protein.   
Tan et al. (1997) showed that dendritic cells contain a mannose receptor that 
can help mediate the uptake of antigens to MHC II presentation by detecting the 
presence of terminal sugars such as mannose, fucose, and N-acetylglucosamine.  They 
showed that mannose receptor-antigen complexes were endocytosed into small coated 
vesicles and then the peptide alone was transferred to larger vesicles.  This suggested 
the mannose receptor was necessary for internalization, but then released the peptide 
upon transfer into the larger vesicle.  The non-mannosylated antigens were present 
directly in larger vesicles, suggesting that the non-mannosylated antigens were 
internalized through a route separate from the mannosylated antigens.   Both types of 
antigen were then shown to be co-localized in vesicles with the MHC II (Tan et al., 1997). 
In addition to the improved ability of a mannosylated protein to be internalized 
compared to non-mannosylated protein, mannosylation also allows more antigen to be 
presented by the cell.   After the receptor complex is endocytosed, the receptor releases 
its ligand so that it can be processed and transported to the MHC II.  The receptor can 
then be recycled so that more antigen can be bound and endocytosed from the 
surroundings.  The glycosylation of three different T cell peptide epitopes caused a 200-
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10,000 fold more efficient presentation of the antigen to induce proliferation of the 
corresponding peptide specific T cell clone (Tan et al., 1997). 
 In order for the high concentration of antigen on the APC surface to have an 
antitumor effect though, the antigen would need to be loaded onto MHC I so that it 
could target the activation of CD8+ cytotoxic T cells that could then kill the tumor cells 
and prevent the tumor from growing.  Since the normal pathway for extracellular 
antigens to be presented is through the MHC II molecule, cross-presentation of the 
antigen peptides must occur within the cell in order to be associated with an MHC I 
molecule.  A study by Apostolopoulos et al. (1995) showed that the oxidation or 
reduction of mannan conjugated to an antigen controlled which T cell effectors were 
activated upon antigen presentation.  If the mannan was oxidized, the antigen caused a 
high activation of cytoxic T lymphocytes (CD8+ T cells) and a low amount of antibody 
production.  Reduced mannan caused the opposite, with a low activation of  
T lymphocytes and a high production of antibody against the antigen produced 
(Apostolopoulos et al., 1995).  The antigen used in this study was the human MUC1, a 
protein highly expressed in adenocarcinomas.   
 These results suggested that oxidation of mannan controlled which pathway the 
antigen entered after endocytosis.  This same group later demonstrated that the 
oxidized mannan did cause the MUC1 to target the mannose receptor of dendritic cells 
and enter the MHC I presentation pathway through cross-presentation 
(Apostolopoulos et al., 2000).  This confirmed that glycosylation of a protein to be used 
as a vaccine, especially through the use of oxidized mannan, can lead to a more efficient 
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presentation of the antigen peptide through the use of MHC I presentation pathway. 
The presentation in MHC I would then target the activation of CD8+ cytotoxic T cells for 
an immune response against cells expressing that antigen.  
Burgdorf et al. (2007) showed that cross-presentation occurs specifically through 
the mannose receptor on APCs and endocytosis through the mannose receptor causes 
the antigen to enter a distinct processing pathway specific to presentation in MHC I.  
The mechanisms of antigen uptake investigated were pinocytosis, mannose receptor 
endocytosis, and scavenger receptor endocytosis.  They discovered that pinocytosis and 
scavenger receptor endocytosis placed the antigen in lysosomes that were then specific 
for presentation in MHC II.  The mannose receptor endocytosis however targeted the 
antigen for early endosomes that were then specific for presentation in MHC I  
(Burgdorf et al., 2007).  These APCs were shown to then activate the appropriate 
corresponding T cell to the MHC complex in which the antigen had been loaded.  This 
confirmed that mannose receptor uptake is necessary for cross-presentation of an 
antigen. 
Luong et al. (2007) used a different approach to show that mannose receptor 
could be targeted for increased presentation of a glycosylated antigen through antigen 
protein synthesis in fungi.  Fungi preferentially use mannose when creating  
O- and N-linked glycosylation on their proteins.  Taking advantage of this, they also 
showed that the type of mannosylation affected the immunogenicity of the antigen.  
Ovalbumin produced in yeast cells (glycosylated) and Escherichia coli (non-glycosylated) 
were presented to bone marrow dendritic cells and tested for presentation through a 
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[3H]-thymidine incorporation lymphoproliferation assay of CD8+ T cells.  Not only did the 
mannosylated OVA cause a higher rate of proliferation of CD8+ T cells, but it was 
observed that OVA containing O-linked mannosylation was more immunogenic when 
compared to N-linked mannosylation (Luong et al., 2007).    
Based on these findings, this project attempted to increase the efficiency of 
HER2 presentation to APCs by targeting of the mannose receptor through the formation 
of a glycosylated version of HER2.  As suggested by previous results, glycosylation was 
predicted to increase the cross-presentation of HER2, which would be presented in the 
MHC I and target activation of cytotoxic CD8+ T cells.  This project could provide 
important insight when considering the formation of a novel immunotherapy for HER2 
overexpressing breast cancer. 
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METHODS 
 
 
 
 
Producing EVI in E. coli: 
 
Plating E. coli transfected with EVI: 
Luria-Bertani (LB) agar plates were prepared by dissolving 25 g into 1 L distilled 
water and allowed to solidify.  Using a heat sterilized metal loop, a small amount of 
frozen E. coli containing the plasmid EVIpTriEx was streaked onto the plate.  The plate 
was incubated at 37 °C overnight.    
 
Inoculation of LB broth with E. coli: 
A 25% LB broth solution was prepared and heated to a boil.  After cooling to 
room temperature, 25 mL of LB broth was transferred to a 125 mL flask using a sterile 
pipet.  One microliter of carbenicillin (100 mg/mL) per milliliter of broth and 1 μL of 
chloramphenicol in 50% ethanol (34 mg/mL) per mL of broth was added to the flask.  A 
heat sterilized inoculating loop was used to inoculate the broth with an individual colony 
from a plate of LB agar with E. coli EVIpTriEx streaked on it.  The flask was then 
incubated overnight at 37°C with agitation. 
The next morning the overnight growth was used to inoculate 5 larger flasks.  
One 2 L flask was prepared with 600 mL of LB broth and four 1 L flasks with 350 mL of LB 
broth for a total of two liters.  One milliliter of the growing culture was used to inoculate 
each flask.  The flasks were then incubated at 37 °C with agitation for 4 hrs.  After  
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4 hours each flask appeared cloudy and 1 μL of 1 M IPTG per mL of broth was added to 
each flask.  The flasks were then incubated with agitation overnight at 37 °C. 
 
EVI inclusion body isolation: 
The E. coli LB broth inoculations were transferred from the five flasks into five 
500 mL centrifuge bottles.  The bottles were centrifuged at 3280 x g for 15 min at 4°C in 
a Sorvall RC 5B Plus centrifuge.  The supernatant was removed and the pellets were 
resuspended into 40 mL of Buffer A (50mM Tris, 25% sucrose, pH 8.0) with protease 
inhibitors cocktail set III (Calbiochem) (1:1000 dilution) added just prior to use.  The cells 
were then lysed by adding 100 mL of Buffer B (20 mM Tris, 100 mM NaCl,  
1% deoxycholate, 1% Triton-X, 0.3 mg/mL lysozyme, pH 8.0) per bottle, with lysozyme 
(Sigma) and protease inhibitors at a 1:1000 dilution added just prior to use.  The 
suspensions were mixed for 15 min at room temperature.  After mixing, 1 μL of  
1 mM MgCl2  per mL solution and 0.02 μL of benzonase (Novagen) per mL of solution 
were added to each bottle.  The bottles were mixed for at least 10 more minutes or until 
the viscosity visually decreased.   
The solutions from the five tubes were then combined into two 500 mL 
centrifuge bottles, each with equal volumes.  The 500 mL bottles were then centrifuged 
at 3280 x g for 15 min at 4°C.  The supernatant was discarded by pipetting and the pellet 
was resuspended into 25 mL of Buffer C (20 mM Tris, 100 mM NaCl, 0.5% Triton-X,  
pH 8.0).  More Buffer C was added until each bottle had approximately 150 mL of 
suspension. Thie suspension was centrifuged at 3280 x g for 10 min at 4 °C.  The 
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resulting pellet was washed two more times with Buffer C.  The supernatant was again 
discarded and the pellet was this time resuspended into 25 mL of Base Buffer (20 mM 
Tris, 100 mM NaCl, pH 8.0).  More Base Buffer was added until each tube had 250 mL 
total volume.  The bottles were centrifuged at 3280 x g for 10 min at 4 °C.  The 
supernatant was discarded and the pellet was resuspended into 10 mL Base Buffer.  The 
resuspended pellet was transferred to a 35 mL Oak Ridge centrifuge tube.  The original 
bottle and transferring pipet were washed with an additional 20 mL of Base Buffer.  This 
was then added to the 35 mL Oak Ridge tube.  The two Oak Ridge tubes were 
centrifuged at 11,000 x g for 10 min at 4 °C.  The supernatant was discarded and the 
pellets were stored at -20 °C in the Oak Ridge tubes until further processed. 
 
FPLC of EVI inclusion bodies: 
The pellets in the Oak Ridge tubes were resuspended into 20 mL of solubilization 
buffer (20 mM Tris, 0.5 M NaCl, 6 M GuHCl, 10 mM imidazole).  The tubes were mixed 
for one hour at room temperature to allow for solubilization of the inclusion bodies.  
The tubes were centrifuged at 17,500 x g for 10 min at 4°C.  The supernatant, which 
contained the solubilized E. coli proteins, was removed and filtered through a 0.22 μm 
bottle top filter (Corning).  This solution was then used for fast protein liquid 
chromatography (FPLC). 
The FPLC apparatus was prepared for purification of the EVI by first loading     
100 mM sterile filtered NiSO4 into a 5 mL HiTrap chelating column (GE Healthcare).  The 
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column was then washed with 15 mL of solubilization buffer.  Any protein in the column 
was eluted by washing the column with 15 mL elution buffer (20 mM Tris,  
0.5 M NaCl, 6 M GuHCl , 300 mM imidazole).  The column was again washed with 25 mL 
solubilization buffer while the solubilized E. coli proteins were loaded into a 10 mL loop.  
After the 25 mL of solubilization buffer had run through the column, the protein solution 
was pushed from the loop into the column and 10 mL samples were collected on a 
fraction collector.  After loading the column with protein, the column was washed with 
1.5 mL of solubilization buffer while the loop was loaded with 10 additional mL of the 
solubilized E. coli proteins.  This was then pushed from the loop into the column.  The 
column was washed with another 15 mL of solubilization buffer.  The buffer was 
changed to a 20 mM imidazole solution (a mixture of 3.5% elution buffer and 96.5% 
solubilization buffer) and the column was washed with 15 mL.  A fraction collector was 
used to collect 1.0 mL samples of the 20 mM imidazole column elution during this time.  
The column was washed with 15 mL elution buffer (300 mM imidazole) to elude the EVI 
off the column while continuing to collect 1 mL fractions.  An addition 15 mL 
solubilization buffer was pushed through the column. 
During the FPLC, a chromatograph was obtained, showing the absorbance at  
280 nm of the solution eluted from the column and collected by the fraction collector.  
The peaks on the chromatograph indicate fractions containing protein.  The fractions 
were then combined into groups containing protein from the different steps in the 
procedure: flow through (proteins that did not stick to the column, but flowed through 
when the protein solution was injected into the column), 20mM imidazole fraction 
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(from the mixture of solubilization and elution buffers that would elute loosely bound 
proteins), 300mM imidazole fraction (from washing with elution buffer, which should 
elute the tightly bound EVI protein), and after flow (from the last wash with 
solubilization buffer).  Samples from all groups were subjected to SDS-PAGE gel 
electrophoresis to assure the EVI was primarily in the 300 mM imidazole fraction. 
 
Gel Electrophoresis of FPLC fractions: 
The FPLC fractions were prepared for gel electrophoresis using a protocol to 
remove the 6 M GuHCl from the proteins.  One hundred microliters of the sample was 
mixed with 900 μL of 100% ethanol at -20 °C.  This was placed at -20 °C for 10 min.  It 
was then centrifuged at 7,200 x g in a table top centrifuge for 8 min.  The supernatant 
was carefully removed using a fine tip pipet.  The pellet was resuspended into 1 mL of 
90% ethanol at -20 °C and vortexed briefly.  This suspension was incubated at -20 °C for 
5 min and centrifuged as described for 8 min.  The supernatant was again carefully 
removed.  The pellet was allowed to air dry for 5 min and resuspended into 65 μL 
distilled water, 10 μL 500mM DTT, and 25 μL LDS-PAGE buffer (Invitrogen) for a total 
volume of 100 μL.  Each sample was heated at 70-80 °C for 10-15 min. 
The samples were loaded onto an 8% Tris-Glycine gel (Invitrogen) in a gel box 
filled with MOPS-SDS buffer (Invitrogen).  After the wells were loaded, 500 μL of 
NuPAGE antioxidant was added to the upper chamber of the gel box, moving the tip 
across the chamber as it was expressed.  The gel ran for 30-35 min at 200 volts.  The gel 
was removed from the boxed and stained with Simply Blue Safe Stain (Invitrogen) with 
19 
 
agitation overnight.  The gel was de-stained with distilled water for several hours, and 
archived using cellophane sheets and Dry-ease solution (Invitrogen).   
 Fractions containing EVI were identified by the presence of a well defined band 
on the gel at around 56,000 Daltons based on protein standards.  The fractions 
containing EVI were combined and prepared for refolding and dialysis.   
 
Estimating protein concentration: 
Before dialysis, the combined fractions were tested to estimate their protein 
concentration using a spectrophotometer.  A sample of the combined fractions was 
diluted 1:10 by mixing 900 μL of solubilization buffer in a cuvet with 100 μL sample.  
Using solubilization buffer as the blank, the absorbance of the sample was taken at  
280 nm.  The approximate concentration of the sample was then calculated, based on a 
protein solution with an absorbance of 0.682 at 280 nm having a concentration of 1 g/L.  
 
Dialysis of FPLC fractions/EVI sample:  
 The combined fractions to be refolded were diluted with Diluent Buffer (20 mM 
Tris, 6 M Guanidine HCl, 0.5 M NaCl, 2 mM EDTA) to a concentration of 0.3 mg/mL 
sample in 12 mL total volume.  Prior to refolding, DTT was added to the sample to a final 
concentration of 2 mM in a total volume of 3 mL.  For example, when the approximate 
concentration of the protein was 1.5 mg/mL a volume of 2.4 mL was required for a 
concentration of 0.3 mg/mL in 12 mL.  Therefore, the 2.4 mL of sample was first mixed 
with 6 μL 1M DTT, and 594 μL diluent buffer. This mixture was incubated at 37°C for  
20 
 
30 min.  After the incubation, 9 mL of diluent buffer was added to the mixture, bringing 
the total volume to 12 mL.  The sample was then chilled to 4 °C. 
 The 12 mL sample was injected into a Slide-A-Lyzer Dialysis Cassette (Pierce) with 
an 18 g needle according to the manufacturer’s protocol.  The cassette was placed in a 
float and allowed to dialyze overnight at 4 °C while spinning in renaturation buffer (100 
mM Tris, 0.5 M Arginine, 2 mM EDTA, pH 8.0).   The buffer was then switched to fresh 
renaturation buffer and the sample was allowed to dialyze for nine additional hours.  
The buffer was switched to a phosphate buffered saline (PBS) solution and left to dialyze 
overnight.  The solution was then switched to a fresh PBS solution and allowed to 
dialyze for an addition eight hours.  The EVI solution was removed from the dialysis 
cassette using an 18 g needle and placed into a sterile 15 mL centrifuge tube.  This was 
stored at 4 °C until the solution was ready to be quantified and concentrated. 
 
Quantifying protein solution: 
 The concentration of the EVI protein solution, now refolded and in PBS, was 
found using the Qubit flurometer (Invitrogen) according to the manufacturer’s protocol.  
Four samples were prepared, three standards and one sample of the EVI solution.  First, 
Quant-iT Reagent was diluted 1:200 into Quant-iT buffer to make the Quant-iT working 
solution.  Each sample was then diluted 1:20 in the working solution.  The standard 
samples prepared were at protein concentrations of 0, 200 and 400 μg/mL.  Each 
sample was incubated at room temperature for 15 min.  The Qubit was calibrated using 
the standard samples prepared.  The QF value of the EVI sample was then found using 
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the Qubit flurometer and used to calculate the concentration of the EVI solution 
according to the following equation: 
  Concentration of sample = QF value x  200  
            X 
(where X is the volume in μL of the EVI sample diluted in working 
solution)  
 
 
Concentrating protein solution: 
 The EVI solution was concentrated using an Amicon Ultra-15 Centrifugal Filter 
Device (10,000 MWCO).  The filter device was rinsed with PBS prior to centrifugation of 
the sample by adding 4 mL of PBS to the filter and centrifuging for 15 min at ¾ max 
speed on the Fisher Scientific Centrific centrifuge with a swinging bucket rotor.  Any PBS 
remaining in the filter device was then discarded and the sample was added to the top 
of the filter device.  The sample was centrifuged at ¾ max speed for 15 min intervals 
until the volume remaining in the top of the filter device approached 1.5 mL.  It was 
then centrifuged at ¾ max speed for 5 min intervals until there was about 1.0 mL 
remaining in the device.  This was then transferred to a 5 mL syringe and filtered 
through a 0.22 μm filter into a 1.5 mL sterile tube.  The concentration of the EVI was 
calculated based on the starting concentration, starting volume, and the final volume of 
the solution.  The EVI was then stored at -20°C until it was used as an antigen in the B3Z 
assay. 
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B3Z Assay using RPMI media: 
Splenocyte preparation in RPMI: 
 The spleen was removed from a C57BL/6 mouse using aseptic techniques and 
placed into a 10 mL of Roswell Park Memorial Institute (RPMI) 1640 medium.  In a  
class II biosafety cabinet, two frosted tip microscope slides sterilized in 70% ethanol and 
washed with sterile PBS were used to homogenize the spleen into the 10 mL of medium, 
using the rough side of the frosted tips.  The medium was transferred to a 15 mL 
centrifuge tube.  The plate was washed with an additional 5 mL of medium, which was 
added to the 15 mL centrifuge tube.  The tube was centrifuged at 1250 rpm in an 
International Equipment Company Model HN-S centrifuge for 5 min.  The supernatant 
was aspirated and the pellet was resuspended into 1 mL of red blood cell lysing buffer 
(Sigma).  After a one minute incubation in the red blood cell lysing buffer, 14 mL of RPMI 
medium were added to the tube.   The tube was centrifuged at 1250 rpm for 5 min.  The 
supernatant was aspirated and the pellet was resuspended into 7 mL of complete RPMI 
medium (10% FBS, 1% L-glutamine, 1% kanamycin, 1% NEAA, 1% sodium pyruvate, 1% 
HEPES, 0.1% 2-β-mercaptoethanol, 0.22 μm sterile filtered).  The cell suspension was 
transferred to a 25 cm2 cell culture flask and incubated for 4-5 hours at 37 °C and  
5% CO2.  
 
Cell counting: 
 After the 4-5 hour incubation, splenocytes adhering to the plastic were counted 
using a hemocytometer as described in Barker (1998).  The B3Z cells were also counted 
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in the same fashion before adding them to the plate with the antigen and splenocytes.  
The cells were prepared for counting by aspirating off the medium in the culture flask 
and adding 10 mL of new medium to the flask.  The flask was scrapped using a cell 
scraper.  The cell suspension was then transferred to a 15 mL centrifuge tube.  The 
suspension was mixed briefly by inverting the tube.  A 40 μL sample was taken from the 
cell suspension and mixed with 40 μL of trypan blue (Gibco).  The mixture was pipetted 
onto the hemocytometer and the cells located in the four outer 5 x 5 corner squares 
were counted.  The concentration of the cells in the suspension could then be calculated 
according to the following equation: 
Cell concentration =  # cells counted on hemocytometer  x 2 x 10,000 
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The cell suspension in the 15 mL centrifuge tube was centrifuged in an IEC Model 
HN-S centrifuge at 1250 rpm for 5 min. The medium was aspirated off and the pelleted 
cells were resuspended into the correct volume of medium so that the B3Z cells would 
have a final concentration of 1.4x106 cells/mL and the splenocytes would have a 
concentration of 2.6x106 cells/mL.  
 
Plate set-up: 
A 96 well plate was set up with a serial dilution of antigen, starting with the 
highest concentration in row A.  The antigen was diluted to the highest concentration in 
PBS, to a total volume of 200 μL.  The wells in rows B-H were then filled with 100 μL of 
PBS.  The serial dilution was started by taking 100 μL from row A and mixing it with the 
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100 μL of PBS in row B.  This was continued through row G.  Row H was then left with 
only 100 μL of PBS as a negative control.  Each well had 50 μL of splenocyte cell 
suspension and 50 μL of B3Z cell suspension at the concentrations listed above added.  
The plate was incubated for 24 hours at 37 °C and 5% CO2 before preparing it for a  
β-galactosidase luminescent reading.   
 
B3Z Assay super-activating splenocytes: 
Splenocyte Preparation in AIM-V medium: 
 Splenocytes prepared in AIM-V medium were initially isolated in the same 
process as described for the RPMI preparation.  The only difference in the procedure 
was to use AIM-V medium throughout the process and then complete serum free AIM-V 
medium (1% L-glutamine, 1% Penicillin-Streptomycin, 1% NEAA, 1% Sodium Pyruvate, 
1% HEPES, 0.1% β-mercaptoethanol, 0.22 μm sterile filtered) for the final resuspension 
before transferring the splenocytes to the culture flask for incubation. 
 
Plate set-up: 
 The B3Z assay using AIM-V and Iscove’s Modified Dulbecco’s Medium (IMDM) 
was set up using the same serial dilution of antigen as described in the B3Z assay using 
RPMI medium.  Each well containing antigen and PBS had 5 μM ionomycin added to it.  
Finally, 100 μL of splenocytes at a concentration of 1.3x106 cells/mL in complete serum 
free AIM-V medium was added to each well.  The plate incubated for 48 hours at 37 °C 
and 5% CO2.   
25 
 
 The plate was prepared for the addition of B3Z cells by centrifuging at 1250 rpm 
for 5 min in an IEC Model HN-S centrifuge.  The cells were washed twice with 100 μL of 
IMDM medium.  After centrifuging the plate again for 5 min at 1250 rpm, the 
supernatant was aspirated off the cells were resuspended into 100 μL complete IMDM 
medium (10% FBS, 1% penicillin-streptomycin, 1% NEAA, 1% sodium pyruvate,  
1% L-glutamine, 1% HEPES). 
 B3Z cells in complete IMDM medium were then counted as described above, and 
100 μL of the B3Z cell suspension at a concentration of 7.0x105 cells/mL was added to 
each well containing 100 μL splenocytes in complete IMDM medium.  The plate was 
then incubated for an addition 24 hours at 37 °C and 5% CO2 before preparing it for a  
β-galactosidase luminescent reading. 
 
β-galactosidase Luminescent readings: 
 The plate was prepared for a luminescent reading by centrifuging for 5 min at 
1250 rpm.  The supernatant was discarded and the cells were washed with 200 μL of 
PBS.  This process was repeated one more time.  Into each well was added 50 μL of 
Mammalian Protein Extraction Reagent (MPER) (Pierce).  The plate was shaken gently 
on a microplate shaker for 5 min.  The Clontech Luminescent β-galactosidase detection 
kit II reaction solution was prepared by diluting the reaction substrate 1:50 into the 
reaction buffer.  The β-galactosidase reaction solution was allowed to warm to room 
temperature. 
26 
 
 After shaking for 5 min, β-galactosidase positive control (Clontech) was added to 
the plate.  The β-galactosidase positive control was first diluted 1:2000 into PBS.  This 
was diluted further, 1:5, into PBS.  The final dilution was used to start a serial dilution of 
β-galactosidase positive control by placing 100 μL of the final dilution into well A12 on 
the plate.  Wells B12-H12 were filled with 50 μL of PBS.  The dilution was started by 
taking 50 μL from well A12 and mixing it into well B12.  The serial dilution was continued 
through well G12.  Well H12 contained only PBS. 
 The β-galactosidase reaction solution was added to the plate by dispensing  
150 μL into each well containing 50 μL of cells in MPER and each well containing the β-
galactosidase positive control.  The plate was incubated for 1 hour at room 
temperature.  The plate was then read using a GloRunner microplate luminometer 
(Turner Biosystems) and the GloRunner DXL software or the Modulus Microplate Reader 
(Turner Biosystems). 
 
 Fixing Splenocytes with Glutaraldehyde: 
 Splenocytes isolated into AIM-V media, as described previously, were incubated 
for 4 hrs at 37°C and 5% CO₂.  A 96 well plate was set up with serial dilutions of antigen 
as described for the B3Z assay using RPMI.  The splenocytes were allowed to incubate 
with the antigens for 15 min at 37°C and 5% CO₂.  After 15 min, half the wells containing 
splenocytes at each antigen concentration were fixed with glutaraldehyde, as described 
by Hosken et al. (1989).  Glutaraldehyde was prepared fresh by diluting to a final 
concentration of 2% in Hank’s buffered salt solution (HBSS).  This was added to the 
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splenocyte cell media in each well to a final concentration of 0.05%.  The plate was then 
incubated for one hour at 37 °C and 5% CO₂.  B3Z cells were then added to the plate in 
IMDM media as described for the super-activating method and the plate incubated for 
an additional 4 hours at 37 °C and 5% CO₂ before preparing for a β-galactosidase 
luminescence reading.       
 
Activating B3Z cells with PMA/ionomycin:  
To directly assay for β-galactosidase production in the B3Z cells, phorbol 12-
myristate 13-acetate (PMA) and ionomycin were used to activate the B3Z cells as 
described by Karttunen et al. (1992).  A 96 well plate was set up with a serial dilution of 
PMA and ionomycin, starting with 10 ng PMA and 5 μM ionomycin as the highest 
concentration.  B3Z cells (100 μL) were then added to each well at a concentration of 
7.0x105 cells/mL in either complete IMDM media, complete RPMI, or cells that had been 
switched from complete RPMI to IMDM media.  The plate was incubated at 37 °C and 
5% CO₂ for 4 hrs before preparing for a β-galactosidase luminescence reading.    
 
Enzyme Linked Immunosorbant Assay (ELISA) of splenocytes: 
 To assay for SIINFEKL presentation in the MHC I without using the B3Z cells, an 
ELISA was conducted on the splenocytes alone.  Splenocytes were isolated into 
complete serum free AIM-V media as described previously.  A 96 well plate was set up 
with a serial dilution as described for the B3Z assay with RPMI.  Splenocytes  
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(100 μL) were added to the plate and allowed to incubate for 48 hrs at 37 °C and 5% 
CO₂.  The plate was centrifuged at 1250 rpm and the supernatant discarded.  The 
splenocytes were fixed by adding 200 μL of 4% formaldehyde to each well and 
incubating at room temp for 10 min before discarding the formaldehyde.  Each well was 
rinsed three times with 200 μL PBS.  The wells were blocked by washing with goat serum 
diluted 1:20.  The goat serum (100 μL) was added to each well, and incubated for 5 min 
at 37 °C and 5% CO₂ before washing two times with 100 μL PBS.  This blocking process 
was repeated two more times. One hundred microliters of the primary antibody  
(25-D1.16, anti-mouse MHC I bound to the peptide SIINFEKL, diluted 1:1000) was added 
to each well.  The plate incubated 60 min at 37 °C and 5% CO₂. 
 The plate was washed three times with 100 μL PBS, before adding 100 μL of 
horseradish peroxidase Avidin D (diluted 1:500) to each well.  This incubated 60 min at 
37 °C and 5% CO₂.  The plate was again washed three times with 100 μL PBS.  The 
secondary antibody was detected using the Thermo Scientific Super Signal ELISA Pico 
Chemiluminescent Substrate according to the manufacturer’s protocol.  The substrate 
(100 μL) was added to each well.  The plate was mixed for one minute on a plate shaker.  
The luminescence was read on the Modulus Microplate Reader (Turner Biosystems). 
 
Immunofluorescence of B3Z cell T cell Receptor: 
Plating B3Z cells:  
A 24 well plate was set up with BD BioCoat Poly-L-Lysine 12 mm round coverslips  
(BD Biosciences) in wells 1 and 2 of rows A and B.  The wells were washed with  
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70% ethanol and then PBS.  Two flasks of B3Z cells (one with the old cells that had been 
in culture in the lab for over a year and the other with the new B3Z cells received from 
the University of California at Berkeley, courtesy of Dr. Nilabh Shastri) were scraped and 
transferred to a 15 mL centrifuge tube.  The cells were centrifuged for 5 min at  
1250 rpm.  The supernatant was discarded and the cell pellets were resuspended into 
10 mL of complete RPMI.  Depending on the size of the pellet formed, either 150 μL or 
300 μL of cell suspension was added to the wells containing the round cover slips.  The 
final volume in each well was brought to 1 mL with complete RPMI media.  The plate 
was incubated overnight at 37 °C and 5% CO₂. 
 
Measuring Immunofluorescence: 
 The media was aspirated from each well and 1 mL of 4% formaldehyde was 
added to fix the cells to the cover slips, incubating for 10 min at room temperature.  The 
formaldehyde was aspirated and the wells were rinsed twice with 1 mL PBS.  The wells 
were blocked with goat serum by adding 25 μL of goat serum to each well, incubating 
for 5 min at 37 °C and 5% CO₂, and washing twice with 1 mL BD Pharmigen staining 
buffer (BD Biosciences).  This blocking procedure was repeated two more times.  The 
primary antibody, a mouse monoclonal antibody specific to TCRα and TCRβ (Abcam), 
was diluted 1:100 in staining buffer and 25 μL was added to each well.  The plate was 
incubated for one hour at 37°C and 5% CO₂. 
 Each well was washed three times with 1 mL staining buffer over a period of  
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5 min.  The secondary antibody, biotin conjugated anti-mouse IgG (BD Biosciences), was 
diluted 1:50 in staining buffer and 25 μL was added to each well.  The plate was 
incubated for an additional hour at 37 °C and 5% CO₂.  The wells were washed three 
times with 1 mL staining buffer over 5 min.   
 The plate was taken into the darkroom and all subsequent steps were done in 
the dark.  Streptavidin-FITC (BD Biosciences) was diluted 1:25 in staining buffer and  
25 μL was added to each well.  Each cover slip was removed from the well and mounted 
onto a microscope slide with a drop of Vectasheild mounting medium with DAPI (Vector 
Laboratories).  The slides were visualized using an Olympus BX51 Fluorescent Microscope.   
 
Glycosylating Antigens with Oxidized Mannan: 
 The antigen proteins were glycosylated with oxidized mannan as described by 
Apostolopoulos et al. (1995).  Mannan (Sigma) was dissolved to 14 mg/mL in PBS with  
0.01 M sodium periodate and incubated for 60 min at 4 °C.  Ethylene glycol (10 μM) was 
then added to the solution and incubated an additional 30 min at 4 °C.  A HiTrap Q 
Sepharose HP column (GE Healthcare) was equilibrated with 0.2 M sodium 
carbonate/biocarbonate buffer, pH 9.0.  The first 2 mL of void volume was collected.  
This was mixed with 900 μg of antigen and allowed to incubate overnight at room 
temperature.  Electrophoresis performed using the non-glycosylated and glycosylated 
antigens to see if the band for the glycosylated antigen migrated more slowly down the 
gel due to the added molecular weight of the conjugated mannose. 
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Protein Transfection Agent delivery of antigens: 
TransPass-P protein transfection agent: 
 Splenocytes were isolated as described previously into serum free AIM-V media.  
A 96 well plate was set up with 100 μL of splenocytes at a concentration of  
1.3x106 cells/mL.  The antigens were mixed with the transfection agent TransPass-P 
(New England BioLabs) as described by the manufacturer.   Each antigen was diluted to 
10 μM in serum free AIM-V to a total volume of 30 μL with 0.6 μL TransPass-P.  This was 
incubated for 20 min at room temp before adding 10 μL of the transfection mix to each 
well containing splenocytes.  The plate was incubated at 37 °C and 5% CO₂ for 4 hrs.  B3Z 
cells were added to the plate in IMDM media as described for the super-activating 
splenocytes procedure.  The plate was incubated for an additional 24 hrs at 37 °C and 
5% CO₂ before preparing for a β-galactosidase luminescent reading.   
 
PEI (jetPRIME) DNA transfection agent: 
 Splenocytes were isolated into complete RPMI media as described previously.  A 
96 well plate was prepared by adding 100 μL of splenocytes at a concentration of 
1.3x106 cells/mL to each well.  Each antigen was diluted to a concentration of 1 μg/mL in 
PBS.  To make the transfection mixes, 2 μL of diluted antigen, 4 μL jetPRIME (Polyplus-
transfection) and 100 μL jetPRIME buffer were mixed together and incubated at room 
temperature for 10 min.  Five microliters of the transfection mix was then added to a set 
of wells containing splenocytes.  The plate was incubated overnight at 37 °C and 5% CO₂.  
B3Z cells in complete RPMI (100 μL) were then added to the plate at a concentration of 
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7.0x105 cells/mL.  The plate was incubated an additional 24 hrs at 37 °C and 5% CO₂ 
before preparing it for a β-galactosidase luminescent reading.  
 
PULSin protein transfection agent: 
 Splenocytes were isolated into complete RPMI as described previously.  Before 
adding the cells to the plate, they were washed with complete serum free RPMI to 
remove serum. The splenocytes were then resuspended into complete serum free RPMI 
media.  A 96 well plate was prepared by adding 100 μL splenocytes at a concentration of 
1.3x106 cells/mL to each well.  To make the transfection mixes, 2 μL of antigen diluted to 
1 μg/mL, 4 μL PULSin transfection agent (Polyplus-transfection) and 100 μL 20mM 
HEPES buffer were mixed together and incubated at room temperature for 15 min.  Ten 
microliters of transfection mix was added to a set of wells with splenocytes.  The plate 
incubated overnight at 37 °C and 5% CO₂.  The plate was centrifuged at 1250 rpm and 
the supernatant was aspirated off.  B3Z cells in complete RPMI media were added to the 
plate at a concentration of 3.5X105 in 200 μL.  The plate incubated for 24 hours at 37 °C 
and 5% CO₂ before it was prepared for a luminescent reading. 
 
Statistics and Data presentation 
 Unless otherwise noted, all β-galactosidase luminescent readings are reported as 
the luminescence value measured for the variable in question with luminescence value 
of the respective control subtracted from it.  The zero line on each graph therefore 
depicts the luminescence measurement for the respective control.  For example, in the 
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super-activation with ionomycin assays, the luminescence value reported for EVI at each 
concentration would be the luminescence value measured for EVI on the microplate 
reader with the luminescence value for the ionomycin control subtracted from it.  
Statistical difference was then determined by comparing the original measurement for 
the variable (that did not have the control subtracted from it) and the measurement for 
the control using a student t-test, with p < 0.05 considered significant.   
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CHAPTER 1: B3Z ASSAY USING THE RPMI METHOD 
 
Introduction 
Antigen presenting cells of the immune system have two ways of processing 
foreign materials to initiate an immune response.  External antigens, such as cellular 
debris from infection or tissue damage, are endocytosed and placed into lysosomes.  
Here the antigen is cleaved into smaller peptides.  MHC II molecules produced in the 
Endoplasmic Reticulum (ER) are transported to the lysosome, where they bind the 
peptides.  This peptide/MHC II complex is then presented on the cell’s surface.  Internal 
antigens found in the cytosol, most of which are endogenous to the cell or a result of 
viral infection, are cleaved by proteosomes in the cytosol.  These peptides are then 
transported into the ER, where they form complexes with an MHC I molecules.  The 
complexes are then transported to the cell surface for presentation  
(Raghavan et al., 2008).   
Peptides presented in an MHC II activate T helper cells, which produce specific 
cytokines that in turn activate B cells to produce antibodies specific to the peptide that 
was originally presented in the MHC II.  Antigens presented in the MHC I activate 
cytotoxic T cells, which will then act to destroy any cell displaying the original peptide 
(Raghavan et al., 2008).  This process can be beneficial in the case of tumor antigens.  If 
cytotoxic T cells could be activated to attack tumor antigens found on cancer cells, then 
these cancer cells could be eliminated by the body's own immune system.  In order for 
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the external tumor antigen to be presented in an MHC I, it must undergo cross-
presentation.  
Cross-presentation is the process of presenting an external antigen in an MHC I.  
In order for this to occur, the antigen must be transported into the cytosol.  This has 
been shown to take place through two main types of pathways.  In the vacuolar 
pathway, antigens are brought into the cell by endocytosis in endosomes where they 
are cleaved into smaller peptide fragments by proteases.  These peptides can then be 
loaded into a recycled MHC I present in the endosome.  This complex traffics back to the 
plasma membrane (Raghaven et al., 2008).  The other pathways are known as TAP-
dependent.  TAP (transporter associated with antigen processing) is found in the ER 
membrane.  In these TAP dependent pathways, antigens are endocytosed but 
transported into the cytosol where they can be processed by proteosomes and 
transported into the ER by TAP to be loaded into an MHC I (Raghavan et al., 2008).    
  To test for cross-presentation, antigens containing the peptide sequence 
SIINFEKL were placed in the media of antigen presenting cells (splenocytes) in the 
presence of cytotoxic T cells with T cell receptors (TCRs) specific to the SIINFEKL peptide 
presented in an MHC I (B3Z cell line) and allowed to process the antigens.  If these cells 
were able to present the peptide SIINFEKL in their MHC I, by cross presenting the 
antigen, the B3Z cells would be activated.  The B3Z cells have been engineered so that 
the activation of the TCR activates the LacZ gene, resulting in the production of  
β-galactosidase (β-gal) (Kartunnen & Shastri, 1991).   
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The antigens used in this assay were:  ovalbumin (OVA), which naturally contains 
the SIINFEKL sequence; EVI, which is composed of the external domain of the HER2 
protein, the SIINFEKL sequence, and the internal domain of the HER2 protein;  
EVIrGM, which is EVI conjugated to granulocyte macrophage colony-stimulating factor 
(GM-CSF); and EA2-EVI, which is a variation of EVI with an altered external domain.  
These four antigens were compared for their ability to be presented and activate 
cytotoxic T cells.  EVIrGM was shown to significantly activate the T cells compared to the 
other antigens.  It is predicted that the GM-CSF conjugated to the protein is able to bind 
the GM-CSF receptor on antigen presenting cells and the antigen would be endocytosed 
along with the receptor as it undergoes its normal recycling process. 
After demonstrating that GM-CSF conjugated to EVI significantly increased cross-
presentation, it was hypothesized that GM-CSF alone might increase cross-presentation 
through increased endocytosis and therefore increase presentation of SIINFEKL.  
Granulocyte macrophage colony-stimulating factor acts as a growth factor for 
lymphocytes to promote growth and differentiation.  Both OVA and EVI were tested for 
their presentation in the presence of J558 supernatant.  The J558 cell line produces 
large amounts of GM-CSF.   
 
Methods 
RPMI method:  
Splenocytes were isolated into complete RPMI media as described previously.  
After incubating at 37 °C and 5% CO2 for 4-5 hours, the splenocytes were counted and 
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resuspended into complete RPMI media.  B3Z cells in complete RPMI media were also 
counted and resuspended.  The splenocytes and B3Z cells were added 1:1 to a 96 well 
plate containing antigens serially diluted as described previously, starting with 10 μM of 
antigen.  The antigens used were OVA, EVI, EVIrGM, and EA2-EVI.  Control wells 
contained splenocytes, B3Z cells and PBS.  Control wells did not contain antigen.  The 
plate was incubated 24 hrs at 37 °C and 5% CO₂, and then the amount of β-gal 
production was determined using a GloRunner luminometer and the Luminescent β-gal 
detection Kit II (Clontech). 
 
Serial dilution of GM-CSF: 
 A 96 well plate was set up with the same concentration of antigen (OVA or 
SIINFEKL) in each well, but a serial dilution of J558 supernatant, which acted as the 
source of GM-CSF.  Ovalbumin was added to each well at a concentration of 150 μM in 
PBS.  Twenty-five microliters of J558 supernatant was added to the first wells to start a 
serial dilution as described previously.  A separate plate was prepared with EVI in each 
well at a concentration of 8 μM.  One hundred microliters of J558 supernatant was 
added to the first wells to start a serial dilution.  Control wells contained either antigen 
without J558 supernatant, 25 μL J558 supernatant without antigen, or PBS.  Splenocytes 
and B3Z cells were then added to each well to a 1:1 ratio, bringing the total volume to 
200 μL.  The plates were each incubated at 37 °C and 5% CO₂ for 24 hrs and β-gal 
production was assayed using the Luminescent β-gal detection kit II (Clontech) and the 
GloRunner luminometer.   
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Supplementing with GM-CSF: 
 A 96 well plate was set up with a serial dilution of antigen and equal amount of 
J558 supernatant.  OVA and EVI dilutions were set up starting with 10 μM of each as the 
highest concentration.  One hundred microliters of J558 supernatant was added to each 
well.  The control wells contained J558 supernatant alone.  Splenocytes and B3Z cells 
were then added 1:1 to each well.  The plate was incubated at 37 °C and 5% CO₂ for  
24 hrs before the β-gal production was assayed using the Luminescent β-gal detection 
kit II (Clontech) and the GloRunner luminometer.    
 
Results: 
 Four different antigens were compared for their ability to activate the cytotoxic 
T cell line, B3Z.  The activation of the B3Z cells was determined by measuring the 
amount of β-gal production. The β-gal produced by cells presented with each antigen 
was compared to the β-gal produced by the controls using a student t-test (p < 0.05 
significance).  Since the same concentration of cells was not used for each assay, the 
luminescent reading and antigen concentration are reported per 106 cells.    
Three of the antigens showed significant β-gal production for at least two 
concentrations of antigen.  The EVIrGM showed a much larger activation than the other 
antigens, but was significantly greater than the control at only the highest concentration 
(Figure 1A).  The next largest activation was by the EA2-EVI, which showed significant  
β-gal production at all concentrations except the lowest (Figure 1A).  OVA also showed 
significant β-gal production at four of the lower concentrations, but did not activate the 
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cells very much in comparison to the EVIrGM and EA2-EVI (Figure 1B).  The HER2 antigen 
containing the SIINFEKL sequence (EVI) did not have significant β-gal production at any 
antigen concentration (Figure 1A & 1B). 
 
  
Figure 1:  B3Z Assay using 
RPMI.  Splenocytes and 
B3Z cells were incubated 
with serial dilution of 
antigens for 24 hrs.  The β-
gal production by the B3Z 
cells as a result of 
activation by the peptide 
SIINFEKL presented in a 
MHC I by the antigen 
presenting cell was 
measured by a 
luminescent assay.  The 
antigens used were OVA, 
EVI, EVIrGM, and EA2-EVI.  
All antigens were at a 
concentration of 10 μM 
for the highest 
concentration.  Results are 
reported per 106 cells, 
since different 
concentration of cells 
were used for each 
antigen.  Luminescent 
readings significantly 
greater than PBS control 
are indicated by the stars 
(*), determined by a 
student t-test (p < 0.05). 
Panel A shows all antigens, 
while panel B shows OVA 
and EVI only. 
 
 
 
 
A) 
B) 
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Since the EVIrGM gave the greatest β-gal production by B3Z cells in response to 
the splenocytes presented with the highest antigen concentration, an assay was 
conducted to test if the GM-CSF needed to be conjugated to the EVI, or if it would work 
as a supplement in the media.  The supernatant of J558 cells, collected previously, was 
added to specific set concentrations of antigen to determine the concentration of 
supernatant that would aid in activation of the cells by the antigen without activating 
the cells on its own.  Either 8 μM EVI or 150 μM OVA was added to each well of a plate 
with different concentrations of J558 supernatant.  The serial dilution of J558 
supernatant was then compared to the antigen alone.   
Both EVI and OVA showed significant β-gal production at the higher 
concentrations of J558, with the 100 μL of J558 supernatant added to the EVI 
responding the greatest (Figure 2).  Different concentrations of cells were used for each 
assay, so luminescence is reported per 106 cells.  While the highest concentration of 
J558 supernatant was able to significantly increase the activation of B3Z cells by EVI, it 
did not by itself show a significant increase in β-gal production (data not shown).  When 
compared to cells with PBS instead of antigen, 100 μL of J558 without antigen did not 
cause significant β-gal production. 
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Figure 2: Optimal J558 
dilution.  Splenocytes and 
B3Z cells were mixed with a 
set concentration of 
antigen (8 μM EVI or 150 
μM OVA) and a serial 
dilution of J558 
supernatant.  β-gal 
production by the B3Z 
cells, was measured by 
luminescence per 106 cells.  
Stars (*) indicate 
significantly greater 
luminescence than controls 
(p < 0.05). 
 
 
The 100 μL of J558 supernatant gave the highest response in combination with 
EVI, and alone did not significantly activate the B3Z cells, so it was used as a supplement 
with serial dilutions of antigen.  OVA and EVI were added to splenocytes and B3Z cells in 
serial dilutions, starting with 10 μM of each.  One hundred microliters of J558 
supernatant was then added to each concentration.  Only one concentration of EVI and 
two of the lower concentrations of OVA showed significant readings when compared to 
cells with J558 supernatant and no antigen (Figure 3).  While these readings were 
significantly above control, the luminescence per 106 cells was much lower than the 
EVIrGM itself (Figure 1A). 
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Figure 3:  B3Z Assay 
with J558 supernatant.  
Splenocytes and B3Z 
cells were mixed with 
serial dilutions of OVA 
and EVI with 100 μL of 
J558 supernatant per 
well.  Activation was 
measured by 
luminescent readings 
significantly above the 
control of cells with J558 
supernatant alone, as 
indicated by the stars (*) 
(p < 0.05). 
 
 
 
 
 
Discussion 
 In order for an external or recombinant antigen to have an effective cytotoxic  
T cell response, the antigen must undergo cross-presentation into the MHC I pathway.  
This process occurs in antigen presenting cells through two main pathways.  The amount 
of cross-presentation can be enhanced through alterations of the antigen itself and 
targeting of receptors on the antigen presenting cell’s surface to encourage endocytosis 
of the antigen.  The antigens OVA, EVI, EVIrGM, and EA2-EVI were tested for their 
efficiency of cross-presentation in the MHC I through activation of the cytotoxic T cell 
line B3Z.  
The antigen which caused the greatest response in B3Z cells as measured by the 
most β-gal production and therefore the highest luminescent reading was the EVIrGM.  
The elevated β-gal production by EVI conjugated to GM-CSF may occur because it is able 
to bind to the GM-CSF receptor and be internalized with the receptor.  This would aid in 
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internalizing the antigen, and therefore increase the probability of undergoing cross-
presentation from the external environment into the MHC I.  It was demonstrated that 
the GM-CSF conjugated to the EVI was able to improve cross-presentation when 
compared to the EVI alone. 
While the highest concentrations of EVIrGM showed significant β-gal production, 
the dose response curve was not quite as expected.  Using a serial dilution of antigen, it 
would be expected that the second highest luminescence would be half the 
luminescence of the highest concentration, since the concentration of antigen was 
reduced 50% with each dilution.  This pattern was not observed for any of the antigens.  
This suggests that none of the antigens were presented to their full potential.  While 
some appeared to undergo cross-presentation, none were able to give a response 
correlated to the amount of antigen presented.  The data points themselves also had a 
large variation, making it hard to draw conclusions about the activation of the T cells by 
the splenocytes.  
In addition to EVIrGM, OVA and EA2-EVI also had a moderate increase in 
luminescence compared to controls, with some antigen concentrations significantly 
greater than the control.  Ovalbumin acts as a positive control because it is a native 
protein containing the SIINFEKL sequence.  This shows that OVA is able to be processed 
naturally by the antigen presenting cells and undergo cross-presentation to a certain 
extent.  The EA2-EVI was also able to undergo some cross-presentation, with an even 
higher efficiency than the OVA itself.  This could be due to the extracellular protein 
44 
 
modification, which may have some ability to increase movement into the cell 
cytoplasm independent of endocytosis. 
Following the increased luminescence with EVIrGM, it was tested whether the 
effect of GM-CSF was only seen when conjugated to EVI.  When a serial dilution of J558 
supernatant, containing large amounts of GM-CSF, was added to consistent amounts of 
antigen, it appeared that the more supernatant that was added, the larger β-gal 
production there was.  This may indicate more antigen presentation, or improved cross-
presentation, and is likely due to greater activity of the splenocytes.  When the highest 
concentration of J558 supernatant (GM-CSF source) was added to serial dilutions of 
antigen however, no dose response was seen.  This suggests that the GM-CSF may 
increase cross-presentation when added as a supplement to the media, but is much 
more effective at increasing cross-presentation of the antigen when conjugated to the 
protein.  The ability of GM-CSF to promote lymphocyte growth was not in itself enough 
to increase presentation.   
The EVI antigen alone was not able to be processed by the splenocytes for cross-
presentation as seen in Figure 1.  There was not a significant increase in β-gal 
production at any concentration of EVI.  This indicates that while variations of the EVI 
protein were able to be presented by the antigen presenting cell and activated the 
cytotoxic T cells, EVI alone was not.  The EVI protein would therefore need to be 
modified in order to make it a productive antigen for a vaccine.  One possible method 
may be to glycosylate the EVI in attempt to increase cross-presentation.   
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CHAPTER 2: SUPER-ACTIVATION OF SPLENOCYTES 
 
 
 
Introduction: 
 Anti-tumor immunity by antigens specific to the tumor type could be developed 
to form an effective treatment.  In order to optimize the outcome of such a treatment, 
the tumor antigen would need to be efficiently presented in a high concentration to 
elicit activation of as many T cells as possible.  One way to increase presentation of an 
antigen would be to have more MHC I molecules available in each cell for binding of 
peptides produced from the tumor antigen.  These peptides in the MHC I would then be 
able to activate cytotoxic T cells specific to the antigen.   
 The ionophore ionomycin has been shown to increase the number of MHC I 
molecules within antigen presenting cells by its ability to induce synthesis of several 
cytokines.  Ionomycin acts to increase calcium influx inside the cell, activates protein 
kinase C (PKC) pathways, and induces the production of the cytokines IL-2  
(Chatila et al., 1989) and interferon-γ (Jabrane-Ferrat et al., 1999).  These cytokines are 
involved with the inflammatory response.  In order to increase MHC I production, 
splenocytes were super-activated with ionomycin.  Ionomycin was added to the media 
and incubated for 48 hours along with the appropriate antigens, allowing for maximal 
presentation.   
 Super-activation increases the presentation of antigen, but also increases the 
length of time that presentation must occur.  Hosken et al. (1989) showed that it takes 
as little as 45-60 minutes for OVA peptides to be presented in the MHC I.  While the 
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protein is able to be processed by the antigen presenting cell, and presented on the cell 
surface in a short amount of time, it is unknown how long the SIINFEKL/MHC I complex 
will remain on the cell surface.  In the super-activation assay the splenocytes are 
allowed to process and present the antigen for 48 hrs.  It is questionable whether the 
peptide/MHC I remain on the cell surface for that long. 
Ludewig et al. (2001) demonstrated that the antigen gp33 could be rapidly 
presented in an MHC I and elicit a cytotoxic T cell response.  However, the  
peptide/MHC I complex presentation did not last very long.  One day after presentation 
of the antigen, a cytotoxic T cell response was no longer able to be activated, suggesting 
the peptide/MHC I was no longer presented on the surface of the antigen presenting 
cells (Ludewig et al., 2001).  If this is the case for the OVA peptide, SIINFEKL, presented 
in the MHC I, activation of the B3Z cells may not occur after the splenocytes have 
incubated with the antigen for 48 hrs, even with the aid of the ionomycin super-
activation.  A time course of antigen presentation was conducted to determine if 
antigen incubation time effected the activation of B3Z cells. 
  
Methods: 
B3Z assay super-activating splenocytes with ionomycin: 
 Splenocytes were isolated into serum free AIM-V media as described previously.  
Splenocytes were incubated with ionomycin and serial dilution of antigen for 48 hours 
at 37 °C and 5% CO₂ before adding the B3Z cells.  The antigens used were OVA, EVI, 
EVIrGM, and the peptide SIINFEKL.  After incubating for an additional 24 hours, β-gal 
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production was determined using the Luminescent β-gal detection kit II (Clontech) and 
the GloRunner Luminometer.  A serial dilution of β-gal was used as a standard.  The 
luminescence readings, which correspond to β-gal production, taken from the B3Z cells 
could then be compared to the standard to calculate the amount of β-gal produced.  
The same β-gal standard serial dilution was used for each plate so that luminescence 
readings between plates could be compared. 
 
Time course of antigen presentation: 
Splenocytes were super-activated in AIM-V media as described previously, but 
without antigen.  After the 48 hour incubation, antigen at the same concentration was 
added to each of six plates with splenocytes.  The splenocytes were then incubated for 
1, 2, 4, 8, 24 or 48 hrs with the same concentration of antigen at 37 °C and 5% CO₂ 
before adding B3Z cells.  The antigens used were either 10 μM OVA or EVI.  After adding 
B3Z cells, the plates were incubated an additional 24 hrs before reading the 
luminescence on the GloRunner luminometer. 
 
Results: 
 Splenocytes were super-activated with ionomycin and antigen to determine if 
antigen presentation could be increased.  Ionomycin acts on the splenocytes to increase 
cytokine production, leading to an increase in the number of MHC I produced by the 
cell.  With an increased amount of MHC I available, the antigen presenting cells may be 
able to present more peptides and activate more cytotoxic T cells.  
48 
 
Four different antigens were assayed for their ability to activate B3Z cells: OVA, 
EVI, EVIrGM, and the peptide SIINFEKL.  Only the SIINFEKL peptide showed significant 
activation above the control consisting of cells treated with PBS and ionomycin  
(Figure 4), but this was only at two of the lower concentrations.  EVI and OVA did not 
show significant β-gal production at any concentration of antigen.  Even the EVIrGM, 
which was able to significantly activate the B3Z cells using the RPMI method (Chapter 1) 
was not able to produce significant β-gal production using the super-activating method. 
 
Figure 4:  B3Z Assay 
Super-activating 
splenocytes.  
Splenocytes were 
incubated with 
ionomycin and serial 
dilution of the 
antigens OVA, EVI, 
SIINFEKL and EVIrGM 
for 48 hours.  B3Z 
cells were then 
added for an 
additional 24 hrs and 
assay for activation 
by luminescence.  
The luminescence 
was then compared 
to a β-gal control to find the amount of β-gal produced.  Stars (*) indicate significant β-gal 
production compared to controls (p < 0.05). 
 
 
 
 Since an increased response was not observed with the super-activation of 
splenocytes, a time course of antigen presentation was conducted to determine the 
stability of the presented peptides in the MHC I.  The splenocytes were super-activated 
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with ionomycin for 48 hours before adding the antigen.  The splenocytes were then 
incubated with the antigen for a given amount of time to allow for presentation.   
B3Z cells were then added to the splenocytes to become activated by any SIINFEKL that 
was able to be presented by the splenocytes. 
 Both OVA and SIINFEKL were assayed for antigen presentation over time.  The 
controls of PBS or PBS and ionomycin were also assayed at each time point.  The 
antigens were allowed to incubate with the splenocytes for 1, 2, 4, 8, 24, or 48 hrs 
before adding the B3Z cells.  The time allowed for antigen presentation did not appear 
to affect the activation of the B3Z cells.  At no time point was there significant β-gal 
production by either antigen above the base lines of PBS and PBS with ionomycin 
(Figure 5).       
 
 
Figure 5:  Time course of 
Antigen Presenation. 
Splenocytes were super-
acivated with ionomycin for 
48 hrs before adding 
antigens.  The antigens OVA 
and SIINFEKL incubated with 
the splenocytes for the 
indicated amount of time 
before adding B3Z cells and 
incubating for an additional 
24 hrs to allow for 
activation.  The activation of 
B3Z cells is reported as the 
amount of β-gal produced.  
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Discussion: 
 In an attempt to increase antigen presentation, splenocytes were super-
activated with ionomycin, which acts to increase calcium influx and activate cytokine 
release.  The super-activation however did not increase the presentation of any of the 
four antigens assayed.  The only antigen with β-gal production significantly above the 
PBS plus ionomycin control was SIINFEKL.  This only occurred at two of the lower 
concentrations.  The antigen EVIrGM, which was able to elicit the most β-gal production 
using the RPMI method, was not able to produce a significant amount of β-gal. 
   This raised the concern of how long the peptide will stay presented on the cell 
surface, since the antigens were incubated with the splenocytes for 48 hrs before the 
B3Z cells were added.  If the peptide/MHC I was not able to stay presented a substantial 
period of time, the splenocytes would not be able to activate the B3Z cells, as was 
observed.  Hosken et al. (1989) showed that presentation of OVA peptides took as little 
as 45-60 minutes to be presented on an antigen presenting cells surface.  Ludewig et al. 
(2001) demonstrated that while a specific antigen was able to be presented quickly in 
the MHC I and induce a cytotoxic T cell response, the presented peptides lasted for less 
than one day.   
To investigate this issue, a time course of antigen presentation was done. 
Splenocytes were first super-activated with ionomycin and incubated with antigen for 
set amounts of time before adding the B3Z cells.  There was no difference in B3Z cell 
activation for any of the time points.  The β-gal production was never significantly 
greater than that of the PBS or PBS plus ionomycin controls.  This suggests that either 
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the splenocytes are not able to present the SIINFEKL peptide at all, or the B3Z cells are 
not responding to the presentation.  Even when the peptide SIINFEKL itself was 
presented to antigen presenting cells, the B3Z cells were not activated.  While OVA 
would have to be processed by the cell into the SIINFEKL peptide, it should be much 
easier for the cell to present the peptide, since it should not need to be processed.  This 
however did not appear to be the case.   
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CHAPTER 3: ASSAYS FOR B3Z FUNCTIONALITY 
 
Introduction: 
 The results of the previous experiments have suggested that the B3Z cells are 
unresponsive to peptides presented in the MHC I of murine splenocytes.  This could be a 
result of the splenocytes being unable to process and present the antigens.  However, 
not even the SIINFEKL peptide was able to induce β-gal production by the B3Z cells.  
Instead, it was hypothesized that the B3Z cells were not able to be activated.  In order to 
determine the functionality of the B3Z cells, several assays tested for T cell receptor 
(TCR) presence and activity, as well as the presence of the LacZ gene. 
 To determine if the B3Z cells were able to produce β-gal, they were stimulated 
with a combination of Phorbol 12-Myristate 13-Acetate (PMA) and ionomycin.  The B3Z 
cells are constructed so that the LacZ gene, which codes for β-gal, is under the control of 
the nuclear factor of activated T cells (NF-AT) element of the IL-2 gene.  When the T cell 
receptor (TCR) gets activated by binding the specific MHC/peptide, the receptor sends a 
signal through calcium dependent pathways including protein kinase C (PKC) and 
calmodulin to activate NF-AT, which then stimulates the transcription of IL-2.  Since  
β-gal is under control of the IL-2 enhancer, it will also get transcribed upon TCR 
activation (Karttunen & Shastri, 1991).  The PMA and ionomycin are able to enter the 
cells and simulate TCR activity.  The combination of the two has shown to increase 
calcium influx and activate PKC and calcium-calmodulin pathways (Chatila et al., 1989).   
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They have also been shown to directly activate β-gal production in B3Z cells  
(Kartunnen & Shastri, 1991). 
 If the B3Z cells were able to produce β-gal, the next step would be to look for 
TCR activation.  In order to assay this, splenocytes were fixed with glutaraldehyde to 
prevent protein processing.  When cells are fixed, the SIINFEKL peptide is still able to be 
presented by MHC I molecules already on the surface of the antigen presenting cells.  
Hosken et al., (1989) showed that OVA peptides could be presented on the cell surface 
without internalization.  These peptide/MHC I complexes were then able activate a 
cytotoxic T lymphocyte response (Hosken et al., 1989).  By mixing the splenocytes with 
SIINFEKL and fixing the cells, SIINFEKL should be presented in the MHC I on the surface 
of the cells and should be able to activate the TCR on B3Z cells.  Therefore if the TCR is 
functional, it should cause β-gal production. 
 In another attempt to increase antigen presentation, and therefore activate the 
TCR of B3Z cells, splenocytes were super-activated with a much larger concentration of 
ionomycin.  Ionomycin is able to cause production of the cytokines IL-2  
(Chatila et al., 1898) and interferon-γ (Jabrane-Ferrat et al., 1999).  The supplementary 
effect of ionmycin is to increase the number of MHC I molecules by increasing the 
production of interferon-γ.  Interferon-γ has specifically been shown to up-regulate the 
transcription of the class I MHC heavy chain (Schroder et al., 2004).  For this reason, 
splenocytes were also super-activated specifically with interferon-γ. 
 In addition to up-regulating the MHC I, interferon-γ has been shown to increase 
the number of N-extended peptides formed by proteosomes in the cytosol.  The  
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N-extension binds to a receptor on the ER membrane, allowing it to be transported into 
the ER.  Once in the ER, the N-extension is cleaved off and the peptide is available to be 
combined with an MHC I (Rock et al., 2004).  Not only does interferon-γ increase the 
number of peptides transported into the ER by N-extension, but it has also been shown 
to specifically increase the number of SIINFEKL peptides produced from the processing 
of ovalbumin.  In the presence of interferon-γ, proteosomes form immunoproteosomes 
which are able to increase the number of intact SIINFEKL peptides from 6% in normal 
proteosomes to 11% (Rock et al., 2004). 
 Finally, in order to assay for the presence of the TCR on the B3Z cells surface, an 
immunofluorescence assay was conducted.  Using new B3Z cells obtained from the 
University of California Berkeley, courtesy of Dr. Shastri, the TCR of the new B3Z cells 
were then compared to the TCR of B3Z cells used for all previous experiments.  The 
“old” B3Z cells had been in culture for over a year.  A decreased presence of the TCR 
could explain the lack of activation of the B3Z cells by the splenocytes presented with 
antigens containing the SIINFEKL peptide.   
 
Methods: 
Activating B3Z cells with PMA/ionomycin: 
 B3Z cells were activated with PMA and ionomycin as described previously.  A 
serial dilution of PMA and ionomycin was added to B3Z cells.  After a 4 hour incubation, 
the β-gal production by the B3Z cells was measured by luminescence using the 
Luminescent β-gal detection kit II (Clontech) and the GloRunner Luminometer.  The 
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assay was conducted with B3Z cells grown in IMDM, cells grown in RPMI, and cells that 
were grown in RPMI but then had the media switched to IMDM.   
  
Fixing splenocytes: 
 Splenocytes were isolated into AIM-V media as described previously.  Antigens 
were then added to the splenocytes and incubated for 15 min.  Half of the cells for each 
antigen type were fixed using glutaraldehyde.  The cells were incubated for an 
additional hour before adding B3Z cells.  The B3Z cells were incubated with the 
splenocytes for 4 hrs before determining the β-gal production using the Luminescent β-
gal detection kit II (Clontech) and the GloRunner Luminometer. 
 
Super-activating splenocytes with increased ionomycin concentration: 
 Splenocytes were isolated into AIM-V media as described previously.  Serial 
dilutions of the antigens were added to the splenocytes with 5 μM ionomycin.  Other 
wells containing a serial dilution of OVA were treated with 70 μM ionomycin.  Controls 
were PBS, PBS plus 5 μM ionomycin, and PBS plus 70 μM ionomycin.  After super-
activating for 48 hrs, B3Z cells were added.  After an additional 24 hr incubation, the 
β-gal production was determined using the Luminescent β-gal detection kit II (Clontech) 
and the GloRunner luminometer. 
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Super-activating splenocytes with interferon-γ: 
 Splenocytes were again isolated into AIM-V media as described previously.  
Antigens were plated at a constant concentration and a serial dilution of interferon-γ, 
starting with 200 μM interferon-γ.  SIINFEKL and OVA were both used at 10 μM.  A 200 
μM interferon-γ control alone was used.  The splenocytes were incubated for 48 hrs 
before adding B3Z cells and incubating an additional 24 hrs.  The β-gal production was 
then determined using the Luminescent β-gal detection kit II (Clontech) and the 
GloRunner luminometer. 
 
Immunofluorescence of TCR on B3Z cells: 
 To assay for the presence of the T cell receptor (TCR) on the surface of the B3Z 
cells, an immunofluorescence assay was conducted.  The primary antibody was a mouse 
antibody specific to the TCR. The secondary antibody was specific to mouse IgG and 
conjugated to biotin.  Streptavidin-FITC was then used to detect the biotin.  The FITC 
fluoresced green under the fluorescent microscope.  The cells were stained with DAPI to 
visualize their nucleus, which fluoresced blue.  New B3Z cells, obtained from the 
University of California Berkeley were compared to the B3Z cells used previously that 
had been in culture for over a year for the presence of the TCR. 
 
Results: 
 To assay if the B3Z cells were still capable of producing β-gal, the cells were 
stimulated with a combination of PMA and ionomycin.  Cells grown in the two types of 
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media used in the previous experiments, RPMI or IMDM, were compared.  Cells grown 
in RPMI but switched to IMDM media two days prior were also assayed.  The cells were 
able to produce β-gal as demonstrated by the large luminescence measured (Figure 6).  
All points were significantly greater than the PBS control.  The PMA or ionomycin when 
added individually did not activate β-gal production (data not shown); only the 
combination of the two was able to stimulate β-gal production. The IMDM had a greater 
luminescence compared to the cells grown in RPMI, indicating more β-gal production. 
 
Figure 6:  PMA and 
Ionomycin activation of 
B3Z cells.  B3Z cells grown 
in two different types of 
media were incubated 
with serial dilutions of 
PMA and ionomycin.  The 
β-gal production was 
measured by 
luminescence.  All points 
were significantly  
(p < 0.05) greater than the 
luminescence of the B3Z 
cells treated with only PBS.  
Ionomycin and PMA when 
added individually were 
not able to stimulate B-gal 
production (data not shown).  
 
 
Splenocytes were then presented with either SIINFEKL or OVA and fixed with 
glutaraldehyde to prevent the cell from processing the antigen.  The SIINFEKL should be 
able to combine with MHC I molecules on the splenocyte surface and subsequently 
activate the B3Z cells, if the B3Z cells have a functioning TCR.  The fixed splenocytes 
were able to significantly activate B3Z cells at some antigen concentrations using both 
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the OVA and SIINFEKL compared to the control of splenocytes that were fixed without 
antigen (Figure 7).  The cells presented with OVA that were not fixed also had some 
activation significantly greater than the control cells not fixed but treated with PBS.  The 
cells presented with SIINFEKL did not.  
   
Figure 7: Fixing 
Splenocytes with 
Glutaraldehyde.   
Splenocytes were 
incubated with antigen 
for 15 min before fixing 
with glutaraldehyde.   
B3Z cells were added 
one hour later and 
allowed to incubate for 
24 hrs.  Significant  
(p < 0.05) luminescence 
above the PBS control 
or fixed cells with PBS 
control is indicated by 
the stars (*).  
 
 
 
When splenocytes were super-activated with a large amount of ionomycin  
(70 μM), the cells were able to activate B3Z cells to produce β-gal, but in an antigen 
independent manner.  When SIINFEKL and OVA were presented to the splenocytes and 
super-activated with 5 μM ionomycin as before, there was no significant β-gal 
production above the PBS plus ionomycin control (labeled as PBS + ionomycin in  
Figure 8).  The OVA plus 70 μM ionomycin stimulated significant β-gal production 
compared to the 5 μM ionomycin and OVA.  However the β-gal produciton was 
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significantly less than the 70 μM ionomycin plus PBS.  It was therefore concluded that 
the 70 μM ionomycin was itself causing the activation rather than the OVA (Figure 8). 
 
Figure 8: Super-activating 
splenocytes with increased 
ionomycin.  Splenocytes 
were super-activated with 
14 times the ionomycin as 
used in previous super-
activations.  The antigens 
were all added to 10 μM 
and compared to PBS alone.  
The stars (*) indicate 
luminescence significantly 
above the control of PBS 
alone and 5 μM ionomycin 
(p < 0.05). 
 
 
 
 
 
To avoid the antigen independent activation of the B3Z cells, splenocytes were 
super-activated with interferon-γ, which still increases the number of MHC I molecules 
on the antigen presenting cells.  The splenocytes were incubated with a constant 
concentration of antigen but a serial dilution of interferon-γ to determine what 
concentration would have the optimal effect for super-activation.  The super-activation 
with interferon-γ did not have any effect on the ability of the splenocytes to activate the 
B3Z cells.  There was only one concentration of SIINFEKL with significant β-gal 
production compared to the controls, while the remaining concentrations of  
interferon-γ did not differ from the controls (Figure 9).        
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Figure 9: Super-activating 
splenocytes with 
Interferon-γ. Splenocytes 
were super-activated with 
decreasing concentrations 
of interferon-γ and set 
concentration of antigen to 
determine the optimal 
amount of interferon-γ to 
super-activate splenocytes.  
The antigens OVA and EVI 
were at a concentration of 
10 μM.  Luminescence was 
then compared to the PBS 
control.  Stars (*) indicated 
significant readings above 
the control (p < 0.05). 
 
 
An immunofluorescence study of the B3Z cells was conducted to test for the 
presence of the TCR.  New B3Z cells were obtained from UC Berkeley, and compared to 
the B3Z cells that had been used in all previous experiments and had been in culture for 
over a year.  The TCR was detected using an antibody conjugated to FITC which 
fluoresced green.  The cells were stained with DAPI which fluoresced blue.  As can be 
seen in Figure 10, the new B3Z cells had a much higher density of green staining, 
indicating an increased number of TCR compared to the old B3Z cells.   
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Figure 10:  Immunofluorescence of B3Z cells.  The TCR of B3Z cells was detected using a mouse 
antibody specific to the TCR.  The secondary antibody was specific to mouse Ig and conjugated 
to biotin.  The biotin was then fluoresced green using streptavidin-FITC.  The cells were stained 
with DAPI and fluoresced blue.  Both pictures are magnified at 40X on a fluorescent microscope.  
(A) shows the old cells. (B) shows the new cells from UC Berkeley. 
 
 
 
Discussion: 
 Previous experiments during this project had suggested that the B3Z cells used 
were not able to be adequately activated.  To determine if the B3Z cells were still 
capable of producing β-gal, they were activated with ionomycin and PMA.  The 
ionomycin and PMA act together to increase calcium signaling, leading to the 
transcription of the LacZ gene of the B3Z cell.  The B3Z cells were able to make  
β-gal, and did so in correlation to the amount of ionomycin and PMA added.  This result 
indicates the LacZ gene is intact and functional.  The B3Z cells grown in IMDM media 
showed a greater luminescence and better correlation to PMA and ionomycin 
concentration compared to those grown in RPMI.  
Since the B3Z cells were able to transcribe and produce β-galactosidase, it was 
next assayed whether the TCR was able to recognize SIINFEKL in the MHC I.  This was 
A) B) 
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determined without the splenocytes having to process the antigens by presenting the 
SIINFEKL to the splenocytes and then fixing them with glutaraldehyde.  The SIINFEKL can 
bind to empty MHC I molecules on the surface of the antigen presenting cell.  If the TCR 
of the B3Z cells are functional, the B3Z cell should be activated by the fixed splenocytes.   
Some concentrations of SIINFEKL and OVA were able to stimulate β-gal 
production in B3Z cells exposed to the fixed splenocytes that was greater than the β-gal 
production of the B3Z cells exposed to the fixed splenocytes without antigen control.  
However, there was no correlation between the amount of antigen presented and the 
amount of β-gal produced.  OVA should not be able to bind to MHC I on the outside of 
the splenocyte because only peptides 8-12 amino acids long can fit in the MHC I 
complex (Hosken et al., 1989).  OVA would need to be processed by the cell in order to 
produce the necessary peptides, and therefore served as a negative control.  The 
observation that OVA was able to give readings significantly above control and at about 
the same value as the SIINFEKL that gave significant readings, suggests that B3Z cells 
were not actually being activated by the antigen in the MHC I. 
Presentation of OVA by splenocytes that were not fixed also gave significant 
readings above the PBS control.  While the readings were statistically significant, it was 
interesting to note that they did not differ from the OVA readings obtained from the 
fixed cells.  The unfixed cells presented with SIINFEKL did not significantly stimulate β-
gal production.  It could be assumed that the fixed cells, while able to bind and present 
the SIINFEKL peptide in MHC I molecules present on the cell surface, would not be 
expected to present a significant amount of antigen when compared to cells that were 
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not fixed and allowed to process the antigen.  These results support the conclusion that 
the “old” B3Z cells are not responding to the peptide presented in the MHC I. 
In an attempt to get the splenocytes to present more antigen peptides and 
therefore possibly activate the B3Z cells, splenocytes were super-activated with a large 
(70 μM) concentration of ionomycin.  While the lower concentration (5 μM) of 
ionomycin was not able to cause β-gal production in cells presented with OVA, the 
higher concentration (70 μM) did.  When this higher concentration of ionomycin was 
added to cells with PBS instead of antigen however, an even larger response was seen.  
This demonstrated that it was the ionomycin, and not the OVA, that was activating the 
B3Z cells.   
The ionomycin must have been activating the splenocytes, which then were able 
to activate the B3Z cells, since the ionomycin itself was washed off before the B3Z cells 
were added when the media was changed from AIM-V to IMDM.  The activation of the 
B3Z cells was in an antigen independent manner, since the OVA did not cause an 
increased response when mixed with the high concentration of ionomycin compared to 
the high concentration of ionomycin alone.   
In order to avoid the T cell activation by ionomycin affecting the splenocytes, but 
still be able to get the favorable effect of enhanced MHC I production by the 
splenocytes, interferon-γ was used to super-activate the cells.  Not only should it 
increase the number of MHCs, but it has been shown to increase the amount of intact 
SIINFEKL peptides produced by the proteosomes.  However, when interferon-γ was 
added at differing concentrations to the splenocytes, it had no effect on the β-gal 
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production by the B3Z cells.  We concluded this could be attributed to the lack of a 
functioning TCR. 
To assay if the TCR was still present on the surface of the B3Z cells, an 
immunofluorescence assay was done.  At this time new B3Z cells had been obtained 
from UC Berkeley.  The number of TCRs present on the new B3Z cells could then be 
compared to the B3Z cells that had been used for the previous experiments.  When the 
cells were stained with antibodies specific to the TCR and then detected with FITC, there 
appeared to be a much larger number of receptors on the new cells compared to the 
old.  It appeared that the old cells had lost some of their TCRs, and this may explain the 
low levels of activation by SIINFEKL presented in the MHC I of splenocytes.  The previous 
assays were then repeated using the new cells with the larger number of TCRs. 
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CHAPTER 4: ENZYME-LINKED IMMUNOSORBANT ASSAY OF SPLENOCYTES 
 
Introduction: 
 The goal of this project was to increase the cross-presentation of the tumor 
antigen HER2 by antigen presenting cells.  In order to measure the amount of cross-
presentation, a modified version of the HER2 protein containing the SIINFEKL peptide 
was used.  When presented by antigen presenting cells, it should activate the B3Z cell 
line specific to the SIINFEKL peptide presented in the MHC I.  Activation of the B3Z cells 
had not been observed through the presentation of SIINFEKL from any of the antigens 
presented to the splenocytes, or by the SIINFEKL peptide itself.   In attempt to measure 
the peptide presentation without using the B3Z cells, an enzyme linked immunosorbant 
assay (ELISA) was conducted.  This would provide a way to quantify antigen presentation 
without relying on the activation B3Z cells.  
 
Methods: 
 Splenocytes were isolated into serum free AIM-V media as described previously 
and super-activated with antigen and 5 μM ionomycin for 48 hrs.  OVA, EVI and SIINFEKL 
were all used in serial dilutions.  The splenocytes were assayed by ELISA as described 
previously.  Briefly, the splenocytes were fixed with formaldehyde and the wells were 
blocked with goat serum.  The antibody 25-D1.16 conjugated to biotin was incubated 
with the cells for one hour.  The antibody 25-D1.16 is specific to SIINFEKL presented in 
the MHC I.  The avidin-horse radish peroxidase (HRP) conjugated molecule was added 
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and incubated an additional hour.  The HRP was detected using an ELISA specific HRP 
chemiluminescent detection kit (Pierce).  Controls consisted of splenocytes with PBS 
instead of antigen, splenocytes in media without anything added, and wells without 
cells that were fixed, blocked and washed the same as the wells with cells.    
 
Results: 
 The ELISA of SIINFEKL in the MHC I using splenocytes was meant to provide a 
method of measuring antigen presentation without using the B3Z cells.  The amount of 
SIINFEKL presented in the MHC I was not able to be detected above the luminescence of 
the PBS plus ionomycin control.  None of the antigens (OVA, SIINFEKL, or EVI) stimulated 
significant luminescence above the cells only control (Figure 10).  The presentation of 
SIINFEKL in the MHC I could not be detected using the antibodies and HRP luminescent 
kit. 
 
Figure 11:  ELISA of SIINEKL 
in the MHC I.  Splenocytes 
were super-activated with 
ionomycin and a serial 
dilution of antigen.  
SIINFEKL/MHC I complexes 
were then detected using a 
biotin conjugated antibody.  
Avidin-HRP was used to 
detect the biotin.  HRP was 
detected using a 
chemiluminescent kit.  
Luminescence readings were 
not significantly greater than 
controls with PBS and 
ionomycin for any 
concentration of antigen. 
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 When the highest antigen concentration for each antigen was compared to the 
cells only control or to empty wells that were treated the same, it was observed that the 
cells alone and the empty wells gave the largest luminescent readings.  Both were 
significantly greater than the PBS plus ionomycin control (Figure 12). 
 
Figure 12:  Comparing 
Controls of splenocyte 
ELISA.  The highest 
concentration of each 
antigen in Figure 11 is 
shown compared to the 
controls and empty 
wells.  The stars (*) 
indicate luminescent 
readings significantly 
above that of the cells 
with PBS and ionomycin 
(p < 0.05). 
 
 
 
 
 
Discussion: 
 In order to detect antigen presentation without using the cytotoxic T cell line 
B3Z, an ELISA for SIINFEKL was conducted.  An antibody specific to the peptide SIINFEKL 
presented in the MHC I was used to determine the amount of antigen presentation from 
serial dilutions of the antigens OVA, EVI and SIINFEKL.  No significant presentation could 
be detected using this method.  While the EVI gave some large luminescent readings at 
the smaller concentrations, they were not significantly greater than the PBS control.  
The OVA and SIINFEKL gave no readings greater than the PBS control. 
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 This suggests that either the SIINFEKL peptide is not being presented by the 
splenocytes, or this method was not an accurate way to detect antigen presentation. If 
there was a lot of non-specific binding by the antibody or the avidin molecule, a 
significant reading of SIINFEKL presentation may not be detectable.  This seemed to be 
the case, since the luminescent readings of cells alone or the wells that were processed 
the same as the wells with cells gave luminescent readings significantly above the PBS 
control.  The wells that were blocked with goat serum, washed, and incubated with the 
antibody and avidin in the same process as the wells with splenocytes showed the 
highest luminescence of all the wells.  They were significantly greater than the PBS with 
splenocytes control.  This suggests that there may be non-specific binding to the wells 
that was not corrected by blocking with the goat serum.   
 Considering the cells in media alone, with no PBS or ionomycin added, resulted 
in a luminescent reading that was significantly higher than PBS or PBS plus ionomycin 
controls suggests there was non-specific binding by either the antibody or the avidin.  If 
this is the case, the ELISA, in our hands, does not seem to be an accurate measure of 
antigen presentation.  The new B3Z cells from UC Berkeley were next tested for their 
ability to be activated by splenocytes, since it was demonstrated that they have more 
TCRs than the old B3Z cells used in previous experiments (Chapter 3).  
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CHAPTER 5: ASSAYS USING NEW B3Z CELLS 
 
Introduction 
 After demonstrating that the B3Z cells received from UC Berkeley contained 
more TCRs than the previously used B3Z cells (Chapter 3), the B3Z assays were repeated 
using the new cells (hereafter referred to as new B3Z cells).  With more TCRs available, 
the activation of the B3Z cells should be assayable if the SIINFEKL peptide is presented 
by the splenocytes.  The presentation of the antigens was assayed using the RPMI and 
both of the super-activation methods to find which method gave the greatest activation 
of B3Z cells as determined by β-gal production.  The cells were also fixed with 
glutaraldehyde to determine if the SIINFEKL peptide was entering the cell and 
undergoing the presentation process, or just binding to MHC I molecules on the outside 
of the antigen presenting cells.  
  
Methods 
B3Z assay in RPMI 
 A B3Z assay was set up using the RPMI method described previously.  Fifty 
microliters of splenocytes at a concentration of 2.6x106 cells/mL and B3Z cells at  
1.4x106 cells/mL in complete RPMI were mixed with serial dilutions of the antigens 
SIINFEKL, OVA and EVI starting with 10 μM.  The control was splenocytes and B3Z cells 
with PBS (no antigen).  The plate was incubated for 24 hrs at 37 °C and 5% CO₂ before 
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determining the β-gal production using the Luminescent β-gal Detection kit II (Clontech) 
and a Modulus microplate reader (Turner Biosystems). 
  
Super-activating Splenocytes with ionomycin 
 A B3Z assay was set up to super-activate 100 μL of splenocytes at a 
concentration of 1.3x106 cell/mL for 48 hrs in AIM-V media with 5 μM ionomycin and a 
serial dilution of antigen as described previously.  The dilutions were started with 10 μM 
SIINFEKL, OVA or EVI.  Controls were cells treated with PBS alone or PBS plus ionomycin.  
The media was switched to IMDM and 100 μL of B3Z cells at a concentration of 7.0x105 
cell/mL were added.  The plate was incubated for an additional 24 hrs before 
determining the β-gal production using the Luminescent β-gal Detection Kit II (Clontech) 
and the Modulus microplate reader. 
 
Super-activating splenocytes with interferon-γ 
 Splenocytes were super-activated as described previously in AIM-V media with 
either 10 μM SIINFEKL or OVA and a serial dilution of interferon-γ, starting with 200 μM.  
A serial dilution of interferon-γ without antigen was used to determine if the  
interferon-γ itself was causing activation at each concentration.  After 48 hrs, B3Z cells 
in IMDM were added and the plate was incubated for 24 hrs more.  The β-gal 
production was then measured using the Luminescent β-gal Detection Kit II (Clontech) 
and a Modulus microplate reader.    
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Fixing splenocytes with glutaraldehyde 
 Splenocytes were incubated with antigen for 15 min. and then fixed with 
glutaraldehyde as described previously.  The antigens were SIINFEKL and OVA serially 
diluted starting with 10 μM. The cells were then incubated for one hour before adding 
the B3Z cells and incubating an additional 24 hrs.  The β-gal production was then 
measured using the Luminescent β-gal Detection Kit II (Clontech) and a Modulus 
microplate reader. 
 
Results: 
 The new B3Z cells were first assayed using the RPMI method.  Splenocytes and 
B3Z cells were mixed together with serial dilutions of antigen and incubated for 24 hrs. 
The SIINFEKL caused β-gal production greater than the PBS control (Figure 13).  Not only 
did it cause significant β-gal production at every concentration of SIINFEKL, but it was 
also correlated to the amount of antigen presented.  The OVA and EVI however did not 
give significant β-gal production compared to the control.   
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Figure 13: B3Z assay using 
RPMI method, new B3Z 
cells. Splenocytes and B3Z 
cells were mixed with serial 
dilutions of SIINFEKL, OVA or 
EVI and incubated for 24 hrs.  
The β-gal production was 
then measured as a 
luminescent reading.  All of 
the SIINFEKL readings were 
all significantly above the 
control of PBS, as indicated 
by the stars (*), while the 
OVA and EVI were not 
significant (p < 0.05).  
 
 
 
The splenocytes were then super-activated with ionomycin to determine if the 
presentation of SIINFEKL from the EVI and OVA proteins could be elicited, or if the β-gal 
production from the antigen SIINFEKL could be increased.  The SIINFEKL again produced 
significant β-gal production by the B3Z cells when compared to the control of PBS and 
ionomycin (Figure 14).  The OVA and EVI however did not cause significant β-gal 
production (Figure 14).  
When the SIINFEKL β-gal production by the super-activation method was 
compared to the RPMI method, it had significantly more β-gal production at all 
concentrations except for the 5 μM (Figure 15).  A β-gal standard was used to calculate 
the amount of β-gal produced by the cells in each case.  The luminescent values 
between the two assays could then be compared.  While the super-activation method 
was not able to increase the β-gal production by EVI or OVA presentation, it caused 
significant increase in the presentation of the SIINFEKL peptide compared to the RPMI 
method.   
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Figure 14:  Super-activating 
splenocytes with 
ionomycin.  Splenocytes 
were incubated with a serial 
dilution of the antigens 
SIINFEKL, OVA or EVI and 5 
μM ionomycin for 48 hrs 
before adding B3Z cells.  The 
β-gal production was then 
measured by luminescence.  
The SIINFEKL readings were 
significantly  
(p < 0.05) greater than the 
control of PBS and 
ionomycin. 
 
 
 
 
Figure 15:  Comparison of 
SIINFEL presenation by 
the RPMI method to 
super-activation.  The β-
gal produced by SIINFEKL 
presentation using the 
RPMI method is shown 
compared to the the β-
gal produced when 
SIINFEKL was presented 
with super-activation of 
the splenocytes.  The 
super-activation method 
gave significantly higher 
β-gal production than the 
RPMI method, as 
indicated by the stars 
(*)(p <0.05). 
 
  
 
The splenocytes were super-activated with interferon-γ as done previously.  A 
serial dilution of interferon-γ with either 10 μM SIINFEKL or OVA at each concentration 
of interferon-γ.  The SIINFEKL showed significantly higher β-gal production when 
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compared to the PBS control (Figure 16).  The interferon-γ dilution itself, without 
antigen, was significantly higher than the PBS control at one concentration.  When 
SIINFEKL was compared to the interferon-γ at each concentration, SIINFEKL was 
significantly higher than the interferon-γ alone.  The OVA in combination with 
interferon-γ did not have any significant β-gal production compared to the PBS control. 
 
Figure 16:  Super-
activating splenocytes 
with interferon-γ. 
Splenocytes were 
activated with a set 
amount of antigen, 
either 10 μM SIINFEKL or 
OVA, and a serial 
dilution of interferon-γ 
for 48 hrs.  The B-gal 
produced was then 
compared to the PBS 
control.  (A) SIINFEKL 
produced significantly 
more β-gal than the PBS 
control.  The SIINFEKL + 
interferon-γ was also 
compared to the 
interferon-γ alone at 
each concentration for 
β-gal production and 
was found to be 
significantly greater  
(p < 0.05) as indicated by 
the stars (*).  (B) The 
interferon-γ dilution 
without antigen did not 
differ from the PBS 
control except at  
6.25 μM as indicated by 
the star.   
 
 
 
 
A) 
B) 
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Since the SIINFEKL was presented to the splenocytes using all three antigen 
presentation methods at 10 μM, the β-gal production as a result of 10 μM SIINFEKL 
presentation was compared between the three methods (Figure 17).  The comparison of 
all three methods showed they were significantly different in their β-gal production  
(p < 0.05).  The super-activation with ionomycin gave the most production, while the 
interferon-γ super-activation gave the least. 
 
Figure 17:  Comparing the 
three methods of antigen 
presentation.  The β-gal 
production as a result of 
presentation of 10 μM 
SIINFEKL to splenocytes was 
calculated for each 
presentation method.  The 
RPMI method produced 
significantly more β-gal than 
the Interferon-γ method and 
the ionomycin method 
produced significantly more 
β-gal than the RPMI method.  
Bars with different letters 
are significantly different  
(p < 0.05).     
 
To assay if the splenocytes were processing the antigen, or if the SIINFEKL 
peptide was able to bind to MHC I on the outside of the cell, the splenocytes were fixed 
with glutaraldehyde.  The splenocytes were presented with SIINFEKL or OVA for  
15 min and then half of the splenocytes were fixed.  The β-gal production of the B3Z 
cells mixed with the fixed splenocytes was compared to the fixed PBS control, while the 
non-fixed cells were compared to the PBS control with non-fixed cells.    
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The fixed cells that were presented with SIINFEKL did not cause significant β-gal 
production by the B3Z cells compared to the fixed control cells, with one exception 
(Figure 18B).  The cells presented with SIINFEKL that were not fixed caused significantly 
greater β-gal production at all concentrations when compared to the non-fixed PBS 
control.  When compared to the fixed cells presented with SIINFEKL, the non-fixed 
SIINFEKL presented cells also produced significantly greater β-gal at all concentrations of 
SIINFEKL (Figure 18A). 
The fixed cells presented with OVA did not have significant β-gal production 
when compared to the control cells that were fixed and presented with PBS.  The non-
fixed, OVA presented cells did not differ from the PBS control except at two low 
concentrations (Figure 18B). 
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Figure 18:  Effect of Fixing 
Splenocytes with 
Glutaraldehyde. 
Splenocytes were 
presented with serial 
dilution of the antigens 
SIINFEKL or OVA for 15 
min before fixing half the 
cells with gludaraldehyde.  
The cells were incubated 
for another hour before 
B3Z cells were added and 
then  incubated an 
additional 24 hrs.  (A) The 
SIINFEKL fixed was 
compared to the SIINFEKL 
presented to non-fixed 
cells and was found to be 
significantly lower at all 
concentrations. Fixed and 
non-fixed OVA did not 
differ. (B)The fixed cells 
treated with antigen were 
compared to fixed cells 
with PBS. 
Non-fixed cells were 
compared to non-fixed 
cells with PBS.  Significant 
differences are indicated 
by stars (*) (p < 0.05). 
 
 
Discussion: 
 The new B3Z cells received from UC Berkeley were assayed for their ability to be 
activated by the presentation of SIINFEKL from the antigens EVI, OVA and the peptide 
SIINFEKL itself.  Since the new B3Z cells had been shown to have a larger number of 
TCRs than the old cells, they should be able to recognize antigen presented by the 
antigen presenting cells more robustly.  The new B3Z cells were able to produce 
B) 
A) 
B) 
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significant β-gal production when the splenocytes were presented with SIINFEKL peptide 
using any of the three activation methods. In all three cases the response to SIINFEKL 
corresponded to the SIINFEKL concentration.  This demonstrated that the B3Z cells were 
responding to a difference in presentation of the SIINFEKL peptide by becoming more 
activated with an increase in antigen concentration and therefore an increase in antigen 
presentation. 
 The SIINFEKL was able to cause significantly more activation when presented 
using the super-activation with ionomycin method then with the RPMI method.  It is 
suspected that the increased MHC I production due to ionomycin’s effects on the 
antigen presenting cells caused more presentation of the peptide.  The B3Z cells were 
also able to respond to a difference in presentation of the SIINFEKL peptide by varying 
the concentrations of interferon-γ.  The higher the concentration of interferon-γ used, 
the more SIINFEKL peptide was presented and therefore more activation of B3Z cells 
was observed through β-gal production and detected by luminescence. 
 While all three methods showed significant β-gal production when the cells were 
presented with SIINFEKL, the super-activation with ionomycin caused the most β-gal 
production.  Since all three assays were done with 10 μM SIINFEKL, the β-gal production 
resulting from presentation of 10 μM SIINFEKL was compared between each method.  
The super-activation with ionomycin gave the largest production of β-gal, with the next 
largest from the RPMI method, and the smallest from the super-activation with 
interferon-γ.  Even though interferon-γ has the advantage of making the antigen 
79 
 
presenting cells produce more MHC I molecules, the added effect of other pathways 
activated by ionomycin must also aid in increasing the presentation of SIINFEKL.    
 While the SIINFEKL peptide was able to be presented by the antigen presenting 
cells, the EVI and OVA proteins did not seem to be processed by APCs into the necessary 
SIINFEKL peptide for presentation by the splenocytes.  The EVI and OVA did not give 
significant luminescent readings compared to controls using either the RPMI or the 
super-activating methods.  While super-activating the splenocytes allowed for more 
SIINFEKL presentation, neither the EVI nor the OVA responded appropriately. This is an 
important observation when considering the optimal composition of a tumor vaccine.  It 
suggests that a specific peptide ready to be directly combined with an MHC I would be 
able to mount a larger T cell response than a whole protein that needs to be processed 
by the cell.  It implies that the most efficient and effective vaccine to elicit a cytotoxic T 
cell response is a specific antigenic peptide.  A more detailed study on the peptides 
formed when HER2 is cleaved by proteosomes in the cell and which of these peptides 
are most efficiently cross-presented by antigen presenting cells resulting in the 
activation of cytotoxic T cells may lead to a new agent for vaccine formation.      
 To determine if the antigen presenting cells were actually internalizing the 
SIINFEKL peptide and cross-presenting it to the surface of the cell in an MHC I, the 
splenocytes were presented with SIINFEKL and OVA but then fixed to prevent the cells 
from further processing the antigen.  If the SIINFEKL was simply combining with MHC I 
molecules already on the surface of the cell, then fixing the splenocytes should not 
affect the β-gal production from the B3Z cells in response to the presented SIINFEKL.  
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When the cells were fixed, the SIINFEKL presentation was significantly lower than when 
the cells were not fixed.  This demonstrated that cross-presentation was occurring. 
  One concentration of SIINFEKL in the cells that were fixed was able to cause 
significant production of β-gal when compared to the control of the fixed cells 
presented with PBS.  This suggests that it is possible for the SIINFEKL to combine with 
MHC I already on the surface of the splenocytes as described by Hosken et al. (1989).  As 
expected, the OVA did not cause significant β-gal production when the splenocytes were 
fixed.  The OVA protein is too large to fit in the MHC I already on the cell surface and 
therefore needs to be processed by the cell, so it should not be able to cause β-gal 
production when the cells are fixed, as observed.   
 Since the SIINFEKL was able to cause activation of the new B3Z cells as detected 
by β-gal production, it shows that the model is able to detect cross-presentation despite 
the negative outcomes of previous experiments.  Because this was the case, the EVI 
protein was next conjugated to mannan to assay the original hypothesis that 
glycosylation would increase cross-presentation.   
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CHAPTER 6: GLYCOSYLATION OF EVI AND SIINFEKL 
 
Introduction 
 Glycosylation of proteins has been demonstrated to not only increase antigen 
presentation (Tan et al., 1997), but also increase cross-presentation of the antigen 
(Apostolopoulos et al., 1995) through interaction with the mannose receptor  
(Burgdorf et al., 2007).  In an attempt to increase the cross-presentation of the tumor 
antigen HER2, the EVI variation of HER2 was glycosylated by conjugation to oxidized 
mannan according to Apostolopoulos et al. (1995).  It was then assayed for its ability to 
be presented in the MHC I and cause activation of the cytotoxic B3Z cells.  Since the new 
B3Z cells had been demonstrated to be activated by SIINFEKL presented in the MHC I, an 
increase in the presentation of EVI through glycosylation should be observable. Given 
that the SIINFEKL peptide was the only antigen to be detected by the B3Z cells in this 
study, it was also glycosylated through conjugation to oxidized mannan to determine if 
its presentation would be improved. 
   
Methods 
Conjugating Mannan to antigens 
 Oxidized mannan (Sigma) was conjugated to EVI or SIINFEKL according to 
Apostolopoulos et al. (1995) as described previously.  Mannan was oxidized by sodium 
periodate and eluted through a HiTrap Q Sepharose HP column (GE Healthcare) 
equilibrated with sodium biocarbonate buffer (pH 9.0) to elute only the oxidized 
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mannan.  The oxidized mannan was then incubated with antigen overnight at room 
temperature.  The resulting glycosylated protein was assayed for the degree of 
glycosylation.   
 
Assays for glycosylation of antigens 
 The glycosylated proteins were assayed for glycosylation by electrophoresis and 
using a glycoprotein detection kit (Pierce).  The proteins were first assayed using 
electrophoresis as described previously to determine if the glycosylated antigen 
migrated at a different rate compared to the non-glycosylated antigen due to the added 
molecular weight of the conjugated mannose.   
A glycoprotein carbohydrate estimation kit (Pierce) was used to determine the 
amount of glycosylation of the proteins. To test for carbohydrate content, 50 μL of 
standards and samples were added to a 96 well plate.  Controls were glycoprotein 
detection reagent, oxidized mannan and PBS.  Twenty-five microliters of 10 mM sodium 
meta-periodate (prepared just prior to use) was added to each well and mixed for  
30 seconds on a plate shaker. After incubating for 10 min at room temp, 150 μL of 
glycoprotein detection reagent (prepared just prior to use) was added to each well and 
mixed for 30 seconds.  The plate was incubated at room temp for one hour before 
measuring absorbance at 560 nm using the Modulus Microplate Reader.   
The absorbance of the standards was then compared to the absorbance of the 
samples and controls. A standard curve was produced by subtracting the absorbance for 
the blank (glycoprotein detection reagent control) from the absorbance of the protein 
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standards.  The absorbance of the protein standards with the blank subtracted was then 
plotted with carbohydrate content (%) based on the values provided by the 
manufacturer.  The plot was fit for a linear regression and the resulting equation was 
used to calculate the carbohydrate content of the samples.  If the absorbance of the 
sample was above 5.00, the carbohydrate content could not be calculated since the 
exact absorbance was too high to be read on the microplate reader.   
   In addition, the amount of protein in both the glycosylated and non-
glycosylated samples was quantified using the Qubit Flurometer as described previously 
to determine the concentration of protein in the solutions. 
 
B3Z assay using RPMI 
 The glycosylated EVI and SIINFEKL were then assayed for cross-presentation by 
activation of B3Z cells using the RPMI method as described previously.  The glycosylated 
and non-glycosylated antigens were mixed with splenocytes and B3Z cells and incubated 
for 24 hrs.  The controls were oxidized mannan, diluted oxidized mannan (at the same 
dilution as the glycosylated SIINFEKL, 1:60) and PBS. The β-gal production was then 
determined using the Luminescent β-gal detection kit II (Clontech) and the Modulus 
Microplate Reader. 
 
Results 
 The antigens EVI and SIINFEKL were conjugated to oxidized mannan as described 
by Apostolopoulos et al. (1995).  To determine if the proteins were glycosylated, a gel 
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electrophoresis was conducted on the glycosylated proteins and the non-glycosylated 
proteins.  When the electrophoresis was performed, the bands for the glycosylated EVI 
were not visible on the gel (Figure 19A).   The lanes containing the glycosylated EVI had 
a dark stained area where the protein was loaded into the well.  It was hypothesized 
that the glycosylated EVI was too large to enter the gel.  The bands in the lanes with 
glycosylated SIINFEKL did appear to shift slightly compared to the non-glycosylated 
SIINFEKL. The bands are very faint, but when looking at the leading edge of the 
glycosylated band compared to the leading edge of the band for the non-glycosylated 
SIINFEKL, it did not migrate as far down the gel, (Figure 19 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Electrophoresis of Glycosylated Antigens. The glycosylated proteins were 
electrophoresed on a Tris-Glycine gel along with the non-glycosylated version of the protein to 
determine if glycosylation had occurred.  Panel A depicts the gel with EVI.  From left to right, 
lane 1 is the molecular weight standard Mark 12 (Invitrogen).  Lanes 2 and 4 are the glycosylated 
EVI at 5 and 15 μL respectively.  Lanes 3 and 5 are the non-glycosylated EVI at 5 and 15 μL 
respectively, with the EVI protein appearing as the darkest band closest to the wells.  Lane 6 is 
the molecular weight standard See Blue (Invitrogen).  Panel B shows the gel with SIINFEKL.  The 
lanes were set up as described for the EVI but with glycosylated and non-glycosylated SIINFEKL. 
 
A) B) 
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EVI and SIINFEKL were both tested for glycosylation using the Glycoprotein 
Carbohydrate Estimation Kit (Pierce).  The non-glycosylated EVI and SIINFEKL were also 
tested for carbohydrate content.  A standard curve was prepared from a set of standard 
glycoproteins (Figure 21).  The linear regression for the standard curve was found to be: 
  Absorbance = 0.2512 (% Carbohydrate) + 0.5857 
Using this formula, the carbohydrate content of the EVI and SIINFEKL were calculated.  
The EVI (non-glycosylated) was found to be 1.3% glycosylated, while the EVI conjugated 
to mannan could not be calculated because the absorbance was over 5.00 and the 
absorbance could not be determined by the microplate reader.    The SIINFEKL was 
estimated to be 0% glycosylated, since its absorbance was only off by 0.01 from the 
blank, was while the SIINFEKL conjugated to mannan could not be calculated because 
the absorbance was over 5.00 (Table 1). 
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Table 1:  Estimation of carbohydrate content of sample proteins.  The carbohydrate content of 
non-glycosylated EVI and SIINFEKL  and glycosylated EVI and SIINFEKL  was found using a 
glycoprotein estimation kit.  The absorbance of the samples was found at 560nm.  The blank of 
glycoprotein detection reagent was subtracted from each absorbance and this value was used to 
compare the sample to the absorbance of standard glycoproteins with known carbohydrate 
content which also had the blank subtracted from them.  Samples with an absorbance over 5.00 
could not be estimated since the exact absorbance could not be detected by the microplate 
reader. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20:  Glycoprotein 
Standard Curve.  A 
glycoprotein standard 
curve was found using the 
glycoprotein standards 
Lysozyme, Bovine Serum 
Albumin, Ovalbumin, Apo-
Transferrin, Fetuin, and 
α1–Acid Glycoprotein and 
the glycoprotein detection 
reagent.  Samples were 
mixed with sodium meta-
periodate and detection 
reagent.  The absorbance 
at 560 nm was then 
measured.  
 
  
Samples 
Protein 
(mg/mL) 
Absorbance 
(560 nm) 
Absorbance 
– Blank 
Estimated 
Carbohydrate 
Content (%) 
Blank 0 3.92 0 0 
EVI 2.5 4.82 0.91 1.3 
EVI 0.25 3.61 -0.30 - 
Glycosylated EVI 0.45 5.00 1.08 - 
Glycosylated EVI 0.045 5.00 1.08 - 
Glycosylated SIINFEKL 0.45 5.00 1.08 - 
Glycosylated SIINFEKL 0.045 5.00 1.08 - 
SIINFEKL 2.5 3.93 0.01 0 
Mannan 0 5.00 1.08 - 
Mannan 
diluted 
1:10 5.00 1.08 - 
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It was uncertain whether the glycoprotein detection reagent was detecting 
glycosylated protein or just the mannan still in solution.  Since the protein bands for the 
glycosylated EVI did not appear on the gel electrophoresis, the protein content of the 
glycosylated EVI and SIINFEKL was measured using the Qubit flurometer (Invitrogen) to 
determine the protein concentration. The glycosylated EVI was found to be 199.4 
μg/mL, while the non-glycosylated EVI at the same dilution was 390 μg/mL.  The 
glycosylated SIINFEKL was found to be 196.2 μg/mL, while the non-glycosylated SIINFEKL 
at the same dilution was found to be 250 μg/mL. 
Finally, the glycosylated and non-glycosylated proteins were assayed for 
presentation by splenocytes using the RPMI method.  Both the glycosylated and non-
glycosylated SIINFEKL resulted in significant β-gal production compared to the controls 
of diluted mannan and PBS respectively.  The glycosylated SIINFEKL approached a 
significant difference at the highest concentration compared to non-glycosylated 
SIINFEKL (p = 0.078).  The glycosylated EVI also showed significantly greater β-gal 
production when compared to the oxidized mannan control and the non-glycosylated 
EVI at each concentration.  The non-glycosylated EVI did not have significant β-gal 
production above the PBS control (Figure 22).  The glycosylated EVI also had significantly 
greater β-gal production than the glycosylated SIINFEKL and non-glycosylated SIINFEKL 
at concentrations of 3.93, 1.96, 0.98 and 0.49 μM.    
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Figure 21: B3Z Assay 
with Glycosylated 
Antigens.  A B3Z 
assay was conducted 
using the RPMI 
method with 
glycosytlated 
SIINFEKL and EVI 
compared to non-
glycosylated SIINFEKL 
and EVI.  Significance 
is indicated by stars 
(*) (p < 0.05).  All 
glycosylated EVI 
readings are also 
significantly greater 
than the non-
glycosylated EVI.   
 
 
 
 
 
 
Discussion 
 
 The antigens EVI and SIINFEKL were conjugated to oxidized mannan, as 
described by Apostolopoulos et al. (1995), in attempt to increase their cross-
presentation.  To test if the antigens were glycosylated, the proteins were separated by 
electrophoresis.  Both glycosylated and non-glycosylated versions of EVI and SIINFEKL 
were assayed.  If the proteins were glycosylated, the protein band should not migrate as 
far on the gel due to the added size of the conjugated mannan.   
A band in the lane loaded with glycosylated EVI was not evident on the gel.  
There was however a dark area in the well of the lane loaded with 15 μL of glycosylated 
EVI, suggesting that the EVI protein may have been glycosylated and was too large to 
enter the gel.  The glycosylated SIINFEKL bands were very faint compared to the non-
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glycosylated SIINFEKL, but the leading edge of the glycosylated band appeared to have 
migrated slightly less compared to the leading edge of the non-glycosylated band.  It 
was difficult to tell if this was a significant difference, as the non-glycosylated SIINFEKL 
bands were very wide, presumably due to the large concentration of SIINFEKL in the 
sample. 
Since the electrophoresis did not irrefutably confirm glycosylation, a 
glycoprotein estimation kit was used to determine the carbohydrate content of the 
proteins.  Both glycosylated and non-glycosylated EVI and SIINFEKL were assayed for 
carbohydrate content, along with the control of oxidized mannan.  According to the 
standard curve formed from glycoprotein standards, EVI that was not conjugated to 
mannan had slight glycosylation.  The SIINFEKL was estimated to not be glycosylated, 
since its absorbance was only 0.01 more than the blank. 
The oxidized mannan control also gave an absorbance over 5.00, indicating the 
estimation kit was not identifying glycoproteins as a whole, but instead corresponded to 
the carbohydrates in solution.  For this reason, the carbohydrate content attached to 
the EVI and SIINFEKL could not be estimated.  The mannan in solution could be causing 
the large absorbance rather than mannan conjugated to the proteins.  
To assay if the proteins were still in solution or to determine if they had been 
degraded in the conjugation process, since the bands had not appeared or were very 
faint on the electrophoresis gels, the concentration of protein for each antigen solution 
was found using the Qubit flurometer.  The glycosylated EVI and SIINFEKL solutions had 
concentrations of 199.4 μg/mL and 196.2 μg/mL respectively.  The non-glycosylated EVI 
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and SIINFEKL were assayed to be 390 μg/mL and 250 μg/mL respectively.  Each solution 
should have had a concentration of 450 μg/mL as this was what the non-glycosylated 
proteins were diluted to prior to the assay.  The glycosylated proteins were also diluted 
to this concentration when mixed with the oxidized mannan to undergo glycosylation.  
This indicated that there was a slight loss of protein through the glycosylation 
procedure.  This could explain the faintness of the SIINFEKL bands on the gel.  This also 
reinforces the hypothesis that EVI is glycosylated, since there is still protein present in 
solution, but the band did not appear on the gel.  This was most likely due to the 
glycosylated EVI being too large to enter the gel.  
 With moderate certainty that the EVI and SIINFEKL were glycosylated by the 
mannan conjugation procedure, they were assayed for their ability to be cross-
presented and activate the B3Z cell line using the RPMI method.  The glycosylated 
SIINFEKL showed similar β-gal production compared to the non-glycosylated SIINFEKL, 
until the highest concentration of antigen.  At the highest concentration, the 
glycosylated SIINFEKL approached a significantly greater β-gal production compared to 
the non-glycosylated SIINFEKL (p = 0.078). 
 The EVI showed a significant difference in β-gal production at all concentrations 
when glycosylated compared to the non-glycosylated.  It was also the first time, during 
this study, that EVI showed a significant increase in β-gal production compared to the 
control.  The glycosylation appeared to increase the cross-presentation of the EVI, 
thereby increasing the number of B3Z cells that were activated and the amount of β-gal 
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produced.  This supported the hypothesis that glycosylation of the HER2 protein EVI 
would increase cross-presentation.   
  Cross-presentation of EVI was achieved through glycosylation, and the amount 
of β-gal produced by B3Z cells in response was even greater than both the glycosylated 
and non-glycosylated SIINFEKL peptide at four concentrations.  This suggests that 
through glycosylation, an antigen can be processed by the cell and presented more 
efficiently than the peptide alone.  When considering a glycosylated antigen as a vaccine 
vector, it would have not only the advantage of increasing presentation of a specific 
antigenic peptide, but also allow for presentation of other peptides within the whole 
protein.  It would be hypothesized that since glycosylation was able to increase the 
presentation of SIINFEKL, it would also increase the presentation of other peptides 
formed from the processing of the HER2 protein.  
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CHAPTER 7: PROTEIN TRANSFECTION AGENTS 
 
Introduction 
 The goal of this project was to increase cross-presentation of the tumor antigen 
HER2.  To accomplish this, the protein needs to be delivered from the extracellular 
environment into endosomes or the cytosol so that it enters into a MHC I presentation 
pathway.  Since antigens presented in the MHC I come from within the cytosol, HER2 
antigen delivered directly into the cytosol by a transfection agent should increase the 
cross-presenation.   
For this reason, several different protein transfection agents were assayed for 
their ability to increase the cross-presentation of the HER2 protein EVI.  The protein 
transfection agents are designed to bind to proteins and chaperone them across the cell 
membrane, into the cell.  Once inside the cell, the transfection agents release the intact, 
still functional protein.  If the protein transfection agents deliver the protein across the 
membrane, it would be more likely for the protein to be processed as an internal 
antigen and therefore be presented in the MHC I. 
 The protein transfection agents assayed for their ability to increase cross-
presentation were TransPass-P (New England Biolabs), jetPRIME PEI  
(Polyplus-transfection) and PULSin (Polyplus-transfection).  All of these agents have 
been demonstrated to successfully transfect living cells with minimal toxicity, according 
to the manufacturers.  The TransPass-P protein transfection agent forms a non-covalent 
bond with the protein to deliver the protein into mammalian cells by endocytosis.  The 
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non-covalent association prevents protein degradation within the endosome when 
endocytosed (New England Biolabs). 
 The jetPRIME (PEI) is a transfection agent intended for DNA transfection, but was 
assayed for its ability to bind and transfect protein.  Polyethyleneimine (PEI) is a 
synthetic branched polymer that has a high cationic charge density.  The cationic PEI 
forms noncovalent interactions with DNA, and promotes cellular uptake by endocytosis 
(Grezelinski et al., 2006).  PEI has been also shown to bind and deliver proteins into 
living cells in vitro and in vivo.  When the PEI binds to the protein, the protein becomes 
cationized and adheres to the cell surface through an ionic charge interaction.  The 
PEI/protein complex is internalized by the cells without binding to a receptor or 
transporter (Futami et al., 2005).  Since PEI has been used as a protein transfection 
agent, the jetPRIME was assayed for its transfection ability with the EVI protein.   
 The third transfection agent used was PULSin (Polyplus-transfection).  PULSin is 
an amphiphile cationic molecule that also forms non-covalent bonds with the protein.  It 
binds to anionic cell-adhesion receptors on the cell surface, which are then internalized.  
Once in the cell, the complexes of PULSin/protein are released into the cytoplasm and 
disassemble (Polyplus-transfection).  If PULSin is able to deliver the EVI protein directly 
into the cytoplasm, it should get processed as an internal antigen and be presented in 
an MHC I, thereby achieving cross-presentation. 
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Methods 
TransPass-P protein transfection agent 
 Splenocytes were isolated as described previously into serum free AIM-V media.  
The antigens were mixed with the transfection agent TransPass-P (New England 
BioLabs) as described by the manufacturer.   Each antigen was diluted to 10 μM and 
mixed with the TransPass-P for 20 min at room temp. The resulting transfection mix was 
added to the splenocytes and incubated at 37 °C and 5% CO₂ for 4 hrs.  B3Z cells were 
added to the plate in IMDM media as described for the super-activating splenocytes 
procedure.  The plate was incubated for an additional 24 hrs at 37 °C and 5% CO₂ before 
determining the β-gal production using the Luminescent β-gal Detection Kit II (Clontech) 
and the Modulus Microplate Reader. 
 
jetPRIME transfection agent: 
Splenocytes were isolated into complete RPMI media as described previously.  
Each antigen was diluted to a concentration of 1 μg/mL in PBS.  To make the 
transfection mixes, 2 μL of diluted antigen, 4 μL jetPRIME (Poly Plus Transfection) and 
100 μL jetPRIME buffer were mixed together and incubated at room temperature for  
10 min.  The transfection mix was added to the splenocytes and incubated overnight at 
37 °C and 5% CO₂.  B3Z cells in complete RPMI were added to the plate and incubated 
an additional 24 hrs at 37 °C and 5% CO₂ before determining the  
β-gal production using the Luminescent β-gal Detection Kit II (Clontech) and the 
Modulus Microplate Reader.  
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PULSin protein transfection agent 
Splenocytes were isolated into complete RPMI as described previously.  Before 
adding the cells to the plate, they were washed with complete serum free RPMI to 
remove serum.  Each antigen was diluted to a concentration of 1 μg/mL in PBS.  
To make the transfection mixes, 2 μL of antigen diluted to 1 μg/mL, 4 μL PULSin 
transfection agent (Poly Plus Transfection) and 100 μL 20mM HEPES buffer were mixed 
together and incubated at room temperature for 15 min.  Transfection mix was added 
to the splenocytes and incubated overnight at 37 °C and 5% CO₂.  B3Z cells in complete 
RPMI media were added to the plate and incubated for 24 hours at 37 °C and 5% CO₂ 
before determining the β-gal production using the Luminescent β-gal Detection Kit II 
(Clontech) and the Modulus Microplate Reader. 
 
Cell Viability Assays 
 Splenocytes and B3Z cells were assayed for viability in the presence of each 
protein transfection agent and the buffer used to make the transfection mix, if 
applicable.  Wells with media alone and cells alone were used as controls.  The cells 
were added to the plate in the same media and incubated for the same period of time 
as described for each transfection agent.  The cell viability was then assayed using the 
Cell Titer Glo Luminescent Assay (Promega) and the Modulus Microplate Reader.  The 
reagent measures cell viability by ATP production. 
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Results 
 The first protein transfection agent applied in attempt to deliver the antigens 
into the splenocytes for presentation as an internal antigen was TransPass-P (New 
England Biolabs).  When SIINFEKL was presented with TransPass-P or alone, the β-gal 
production was greater than the TransPass-P or PBS controls.  In the presence of 
TransPass-P however the SIINFEKL had a significantly small β-gal production when 
compared to SIINFEKL without TransPass-P (Figure 22A).  The TransPass-P did not have a 
significant effect on OVA presentation, as neither the OVA with TransPass-P or OVA 
alone were significantly above the controls.  It appeared that the β-gal produced by OVA 
presentation was lower when presented with TransPass-P, though not statistically 
different (Figure 22B). 
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Figure 22: B3Z Assay 
using the Protein 
Transfection Agent 
TransPass-P. 
 Splenocytes were 
incubated with 
TransPass-P protein 
transfection agent 
and antigen for 4 
hours before adding 
B3Z cells.  The β-gal 
production was then 
measured as a 
luminescent reading.  
Readings significantly  
(p < 0.05) greater 
than the PBS control 
or the TransPass-P 
without antigen 
control are indicated 
by the stars (*).  The 
SIINFEKL and SIINFEKL 
+ TransPass-P differed 
significantly. Panel A 
shows all antigens 
while panel B shows 
only OVA. 
 
 
 
 
 
 
 
 
A cell viability assay to determine the amount of ATP present was also conducted 
to determine if the TranPass-P had an effect on cell proliferation.  There was no 
significant difference in the cell viability of splenocytes and B3Z cells when mixed with 
TranPass-P compared to cells that were not (Figure 23). 
 
A) 
B) 
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Figure 23: Viability of 
cells with TransPass-P. 
Cell Viability of 
splenocytes and B3Z cells 
in the presence of 
TransPass-P was 
measured by ATP 
production through a cell 
titer glo luminescent 
assay.  There was no 
significant difference (p < 
0.05) between cells in 
the presence or absence 
of TransPass-P. 
  
 
 
 
The jetPRIME (PEI) transfection agent (Polyplus-transfection) was next assayed 
for its ability to transfect the antigens SIINFEKL, OVA and EVI.  The SIINFEKL peptide 
gave signifcant β-gal production above the jetPRIME buffer control and the jetPRIME 
with jetPRIME buffer control when combined with jetPRIME or SIINFEKL alone.  In 
combination with the jetPRIME, the β-gal production was significantly lower than the 
SIINFEKL presented in jetPRIME buffer alone (Figure 24A).  When presented with the 
jetPRIME buffer, OVA and EVI both were able to stimulate β-gal production significantly 
greater than the control of jetPRIME buffer.  In combination with jetPRIME transfection 
agent, OVA and EVI did not stimulate significant β-gal production greater than the 
jetPRIME control. For EVI, not only was the β-gal production not significant, but the  
β-gal production was less than the control (Figure 24B). 
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Figure 24:  PEI as a 
protein transfection 
agent. The PEI 
transfection agent 
jetPRIME was incubated 
with splenocytes and 
antigen overnight before 
adding B3Z cells. The β-
gal production was then 
measured as a 
luminescent reading.  
Readings significantly (p 
< 0.05) above the 
jetPRIME buffer control 
or the jetPRIME control 
without antigen are 
indicated by the stars 
(*).  The luminescence 
from β-gal production in 
cells presented with 
each antigen was also 
significantly higher than 
antigen with jetPRIME.   
Panel A shows all 
antigens.  Panel B shows 
only OVA and EVI.  
 
 
 
 
 
 
 
 
A cell viability assay was also conducted on the cells with jetPRIME to determine 
if it had any cell cytotoxicity that would account for the decrease in β-gal production by 
B3Z cells in the presence of jetPRIME compared to control.  While the cells with PEI 
(jetPRIME) did not vary significantly from the cells alone, the cells with jetPRIME buffer 
had significantly more luminescence than the either the cells alone or the cells with 
jetPRIME (Figure 25).   
B) 
A) 
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Figure 25: Cell 
viability in the 
presence of PEI.  Cell 
viability of splenocytes 
and B3Z cells in the 
presence of jetPRIME 
(PEI) was measured by 
ATP production using a 
luminescent assay.  
There was no 
significant difference 
(p < 0.05) between 
cells in the presences 
of PEI and control cells.  
The cells in the 
presence of jetPRIME 
buffer were 
significantly different from the control cells and cells with jetPRIME as indicated by the star (*). 
 
 
 
The protein transfection agent PULSin (Polyplus-transfection) was assayed for its 
ability to transport the proteins into the cytoplasm of the antigen presenting cells and 
therefore increase cross-presentation of the antigens.  When SIINFEKL was presented 
with PULSin or alone it gave β-gal production above the PULSin control or PULISin buffer 
without antigen.  In the presence of PULSin, the β-gal production was significantly lower 
than SIINFEKL presented without PULSin.  The OVA with PULSin stimulated production 
of significant amounts of β-gal compared to PULSin alone, but the OVA with only the 
PULSin buffer was not significantly higher than the control of PULSin buffer.  The β-gal 
production in response to OVA in the presence of PULSin was also significantly higher 
than OVA alone (Figure 26).   
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The EVI with PULSin or EVI alone (with PULSin buffer) did not stimulate a 
significant β-gal production above the PULSin control or PULSin buffer control 
respectively.  The EVI alone resulted in significantly higher B-gal production than EVI 
with PULSin, which resulted in β-gal production lower than its control (Figure 26).  
 
 
Figure 26:  PULSin as a 
protein transfection 
agent. The protein 
transfection agent 
PULSin was incubated 
with splenocytes and 
antigen overnight 
before adding B3Z cells. 
The β-gal production 
was then measured as a 
luminescent reading.  
Significant readings 
compared to the 
controls (buffer or 
PULSin without antigen) 
are indicated by the 
stars (*)(p < 0.05).  The 
luminescence from β-gal 
production in cells 
presented with SIINFEKL 
or EVI was significantly 
higher than SIINFEKL or 
EVI with jetPRIME.  The 
β-gal produced by cells 
with OVA and PULSin 
was significantly higher 
than OVA alone. Panel A 
shows all antigens while 
panel B shows only OVA 
and EVI.  
 
 
 
 
 
 
A) 
B) 
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When the cell viability assay was conducted on splenocytes and B3Z cells in the 
presence of the PULSin protein transfection agent or the buffer, the cells incubated with 
PULSin were not significantly different from the cells alone.  Luminescence resulting 
from ATP production in cells with PULSin buffer however was significantly greater than 
both the cells with PULSin and the cells alone (Figure 27).   
 
Figure 27:  Cell viability in the 
presence of PULSin.  Cell 
Viability of splenocytes and 
B3Z cells in the presence of 
PULSin was measured by ATP 
production through a 
luminescent assay.  There was 
no significant difference 
between cells in the presence 
of PULSin and control cells.  
The cells in the presence of  
PULSin buffer were 
significantly different from 
the control cells and cells with 
PULSin as indicated by the 
star (*)(p < 0.05). 
 
 
 
Discussion 
 Several different transfection agents were assayed for their ability to increase 
the cross-presenation of the antigens SIINFEKL, EVI and OVA.  The transfection agents 
form noncovalent interactions with the proteins and help to transport them across the 
cell membrane.  Once the protein is inside the cell, it was hypothesized that it would be 
processed as an internal antigen and presented in the MHC I.  If this was achieved by the 
protein transfection agents, presentation of the antigens in the presence of the 
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transfection agent should increase the amount of β-gal produced by the B3Z cells as a 
result of activation of the B3Z cells from presentation of the peptide SIINFEKL in the 
MHC I of the splenocytes. 
 The protein transfection agent TransPass-P caused a decrease in β-gal 
production when the antigens were presented with this agent.  The SIINFEKL was able to 
be presented and caused a significantly higher luminescence as a result of β-gal 
production compared to the controls of TransPass-P or PBS alone.  The TransPass-P 
significantly decreased the β-gal production compared to SIINFEKL alone.  This appeared 
to be the case for OVA as well, even though the difference was not statistically 
significant.  The TransPass-P was did not increase cross-presentation, but instead 
seemed to inhibit cross-presentation.  This difference was not due to toxicity of the 
cells, as the cells with TransPass-P gave a similar luminescence in the cell viability assay 
compared to the cells alone.  
 The transfection agent jetPRIME, a variation of PEI, had similar results.  The 
jetPRIME significantly reduced the amount of β-gal produced as a result of SIINFEKL 
presentation when compared to SIINFEKL alone, even though both values were again 
significantly above the controls.  This decrease cannot be attributed to toxicity, as the 
cells alone and with jetPRIME were not significantly different in the cell viability assay.   
The EVI and OVA stimulated β-gal production significantly above the controls 
when presented alone.  Presentation of EVI and OVA with PEI significantly reduces β-gal 
production.  Interestingly, the jetPRIME buffer combined with the antigens (but not 
jetPRIME) stimulated β-gal production in the B3Z cells.  Additionally, increased cell 
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viability occurred when the cells were incubated with jetPRIME buffer compared to 
jetPRIME or no treatment.  However, this difference is accounted for when the cells 
with buffer alone control is subtracted from the luminescent reading of the cells with 
antigen and buffer.   
 As with the other transfection agents, PULSin caused a significant decrease in  
β-gal production when mixed with SIINFEKL compared to SIINFEKL alone.  The SIINFEKL 
presentation was still significantly greater than the controls in both cases.  The EVI 
showed a similar pattern in that it caused more β-gal production alone than in 
conjunction with the PULSin.  As with the jetPRIME, this may be attributable to the fact 
that the cells with buffer alone had increased cell viability compared to cells alone or 
with PULSin.  The decrease is not a result of toxicity of the PULSin, as the cells with 
PULSin were not significantly different from the cells alone during the cell viability assay.   
The OVA in combination with PULSin was the only antigen/protein transfection 
agent combination that displayed significant β-gal production when compared to the 
antigen alone.  The OVA and PULSin also stimulated a significantly greater luminescence 
reading, from β-gal production, when compared to the PULSin alone control.  This 
suggests that the PULSin was able to bind and transport OVA into the cell, increasing the 
amount of cross-presentation.  
In most cases the transfection agents significantly decreased presentation of the 
antigens, as observed by a decrease in β-gal production when in combination with the 
transfection agent.  This decrease could be a result of the transfection agent binding, 
but not releasing the antigen once in the cell, or it could also be caused by the antigen 
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getting endocytosed to get into the cell, but then entering the MHC II pathway, since 
most extracellular antigens that are endocytosed get presented in the MHC II.  Instead 
of increasing cross-presentation, the transfection agents may have been simply 
increasing MHC II presentation, which is not detected with this assay. 
The OVA increase in cross-presentation however demonstrates that it is possible 
to use protein transfection agents to increase cross-presentation.  As shown by the 
decrease in EVI presentation when using the same transfection agent, it implies that the 
right transfection agent for each antigen must be found.  Since proteins are very 
different from one another, compared to DNA or RNA which have the consistent 
backbone structure, it would be important to find a transfection agent that is able to 
bind the protein based on its unique amino acid composition.  Not only must it be able 
to bind the protein, but it also must be able to release it once it gets into the cell.  A 
more serious study of the characteristics of HER2 or other antigens and the properties 
of various transfection agents may lead to the discovery of agents that are able to 
increase cross-presentation as was observed with OVA.   
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SYNOPSIS AND CONCLUSIONS 
 
HER2 overexpression in breast cancer leads to a very aggressive form of the 
disease.  It has been correlated with decreased survival and faster progression when 
compared to breast cancers not overexpressing HER2.  For this reason, HER2 has proven 
to be an excellent target for treatment, as the cancer cells not only depend on HER2 for 
survival, but HER2 has also the been shown to be the initial cause of transforming 
normal cells into cancer (Moasser, 2007a).  Its presence has also been correlated to a 
population of cancer stem cells, which impel tumorgenesis (Korkaya et al., 2008).  By 
targeting HER2 in treatments, the driving force of the cancer can be eliminated, 
effectively preventing the growth of cells overexpressing the receptor. 
The first treatment to take advantage of this concept was the monoclonal 
antibody trastuzumab.  Although the development of trastuzumab has led to a longer 
onset of disease progression and lower death rate at one year (Slamon et al., 2001), a 
relatively large fraction of patients still relapse and one-third of the patients with 
advanced forms of the disease fail to respond to the treatment (Korkaya et al., 2008).  
This along with the severe side effect of cardiac dysfunction in 4.7% of patients treated 
with trastuzumab (Eisenhauer, 2001) encourages the development of a novel treatment 
for targeting HER2 in breast cancer. 
  A treatment option that has recently been explored is the formation of a vaccine 
against HER2.  Evidence has shown that HER2 could be a possible candidate for a 
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vaccine, despite it being a self-protein.  Patients with HER2 overexpressing tumors have 
a pre-existing, though low magnitude, immune response to HER2  
(Bernhard et al., 2002).  A vaccine to boost this pre-existing immunity or elicit a novel 
immunity against HER2 could be the next step at developing a more effective treatment 
for HER2 positive breast cancer. 
 The optimal immune response to a tumor vaccine is the activation of cytotoxic T 
cells.  These cells are specific to antigens on the surface of cells and target them for 
destruction.  Cytotoxic T cells have demonstrated to be required for tumor rejection by 
the immune system (Rohrback et al., 2005).  In order for a vaccine to activate cytotoxic T 
cells, the antigens composing the vaccine need to be presented in a MHC I.  This 
requires the antigen to be cross-presented from the extracellular environment to the 
internal antigen processing pathway.   
 The goal of this project was to optimize the cross-presentation of the tumor 
protein HER2.  Glycosylation has shown to increase antigen presentation in general  
(Tan et al., 1997), as well as to specifically increase the amount of cross-presentation to 
elicit a cytotoxic T cell response (Apostolopoulos et al., 1995).  To determine if this was 
true for HER2, a variation of the HER2 protein, EVI, was conjugated to oxidized mannan.  
The glycosylated EVI demonstrated an increased cytotoxic T cell response when 
glycosylated compared to non-glycosylated as measured by the activation of the 
cytotoxic T cell line B3Z through production of β-gal.  Glycosylated EVI caused 
significantly greater β-gal production compared to non-glycosylated EVI.  This data 
supports previous studies demonstrating that glycosylation of a protein increased cross-
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presentation.  Evidence from this study, as well as from others, indicates that 
glycosylated HER2 antigens should be considered as a viable construct for an effective 
tumor vaccine. 
The glycosylated EVI was able to cause significant β-gal production, even when 
compared to the β-gal produced by the glycosylated and non-glycosylated SIINFEKL 
peptides at four concentrations.    This demonstrated that through glycosylation, an 
antigen can be presented more efficiently than the peptide alone, increasing the 
number of cytotoxic T cells activated in response to that antigen.  A glycosylated antigen 
as a vaccine vector, would have not only the advantage of increasing presentation of a 
specific antigenic peptide, as demonstrated with SIINFEKL presentation, but also allow 
for other peptides within the whole protein to be processed and presented.  It could be 
hypothesized that since glycosylation was able to increase the presentation of SIINFEKL, 
it would also increase the presentation of other peptides formed from the processing of 
the HER2 protein.  
The B3Z cells are specifically activated by the SIINFEKL peptide presented in the 
MHC I.  In order for EVI and OVA to cause β-gal production, they needed to be cleaved 
into fragments and the SIINFEKL peptide presented in the MHC I to elicit B3Z cell 
activation.  Since the SIINFEKL peptide produced more β-gal at the same concentrations 
of antigen as the proteins, it illustrated that the peptide was more efficiently in to 
causing activation then the whole proteins, except when the EVI was glycosylated.  This 
demonstrates that peptides capable of direct presention in the MHC I, without being 
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cleaved by proteosomes or digestive enzymes within the lysosome, can be efficiently 
presented and elicit a strong response by cytotoxic T cells.   
 Data from this study indicates that while the peptide is ready to be presented in 
an MHC I, it still needs to be internalized by the cell and undergo cross presentation in 
order to cause a significant T cell response, as was observed when the splenocytes were 
fixed with glutaraldehyde.  The cells that were fixed and not able to process the antigen 
internally gave significantly less β-gal production compared to cells that were not fixed 
and could process the antigen.  This demonstrated that the SIINFEKL peptide was 
actually undergoing cross-presentation.   
 Further studies of the HER2 protein to find specific peptides that can be directly 
combined with MHC I and elicit a large cytotoxic T cell response could lead to an 
effective vaccine targeting HER2 overexpressing tumor cells.  The peptides naturally 
formed by HER2 break down within the proteosome and lysosome could be examined 
to determine which peptides are responsible for the pre-existing immunity found in 
patients with HER2 overexpressing breast cancer.  Peptides not normally formed by the 
natural processing of HER2 could also be developed to elicit a new immune response to 
less dominant HER2 antigens.  These less dominant antigens would be less likely to 
cause self-reactivity as suggested by Behrnard et al. (2002).  There may also be a larger 
repertoire of T cells specific to these less dominant antigens, since they are less likely to 
be eliminated by negative selection to self antigens because the process is controlled by 
the more dominant antigens (Behrnard et al., 2002).  The self-reactivity observed as 
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cardiac dysfunction in treatment with trastuzumab may be avoided through the design 
of such a vaccine. 
  Glycosylation of the SIINFEKL peptide also appeared to slightly increase 
presentation when compared to the non-glycosylated SIINFEKL at the highest 
concentration.  The β-gal production approached significance, with a p value of 0.078.  
These observations demonstrated the combination of the increased cross-presentation 
observed from the specific peptide along with glycosylation has the possibility to be 
developed into a very effective vaccine agent to a target cytotoxic T cell response to a 
tumor antigen. 
 The SIINFEKL peptide showed significant β-gal production using all methods of 
presentation assayed (the RPMI method, super-activating with ionomycin and super-
activating with interferon-γ), the super-activation with ionomycin method however was 
the most effective.  SIINFEKL presented by super-activation with ionomycin gave 
significantly greater β-gal production compared to the other two methods.  This also 
demonstrated that the SIINFEKL peptide stayed complexed with the MHC I for an 
extended period of time, since the B3Z cells were able to be activated to produce β-gal 
48 hrs after the initial presentation of SIINFEKL.  This method gives an important insight 
into the formation of an ex-vivo vaccine against HER2.  It suggests that supplementing 
the vaccine with ionomycin when pulsing the antigen presenting cells with the desired 
antigen may improve cross-presentation.  
In another attempt to increase cross-presentation, the antigens were also 
presented in the presence of GM-CSF.  The EVI antigen conjugated to GM-CSF, EVIrGM, 
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showed significant β-gal production compared to control at its highest concentration.  
This was one of the first experiments performed for this project, and was most likely 
before the B3Z cells become completely unresponsive to SIINFEKL presentation in the 
MHC I due to a decrease in the number of TCRs.  It was hypothesized that the GM-CSF 
was able to bind the GM-CSF receptor on the cell surface, and the EVI was internalized 
along with the GM-CSF and its receptor, thereby cross-presenting the EVI peptides. 
While the EVIrGM was able to be cross presented, EVI supplemented with  
GM-CSF, but not conjugated to it, did not give significant β-gal production.  One study by 
Knutson et al. (2002) attempted to use GM-CSF as an adjuvant to a HER2 vaccine.  While 
an initial immune response to the vaccine was detectable in two out of four patients, 
the magnitude of the response was low and short lived.  The immunity was not 
detectable five months after the final vaccination.  The observations of this study along 
with the results of this project, support the further study of GM-CSF conjugation to an 
antigen or peptide, rather than using it as an adjuvant.  Conjugation to the peptide has 
demonstrated to increase the amount of cross-presentation and elicit an improved 
cytotoxic T cells response. 
 In an attempt to deliver the proteins directly into the cell and therefore increase 
cross presentation, several transfection agents were assayed.  The only one to 
demonstrate significant increase in the presentation of SIINFEKL in the MHC I, as 
measured by β-gal production in B3Z cells, was the Polyplus-transfection agent PULSin.  
In combination with OVA, it was able to cause significantly greater β-gal production 
when compared to the control.  The PULSin agent also had no significant effect on cell 
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viability when compared to the control.  This demonstrated the possibility of 
transfection agents as adjuvants to vaccine antigens to target the antigen for MHC I 
presentation and activation of a cytotoxic T cell response.   
Since the B3Z cells are specifically detecting SIINFEKL presented in the MHC I, 
and not specific HER2 peptides, this may not be the best model system to represent a 
HER2 antigenic vaccine.  Other HER2 antigens may be processed by the splenocytes and 
presented more efficiently then the SIINFEKL peptide but are not measured using the 
B3Z assay.  Since it has been demonstrated that only 6% of the possible SIINFEKL 
peptides that can be formed from the proteolysis of OVA actually stay intact  
(Rock et al., 2004), it is likely this same ratio would occur from processing EVI.  While it 
appears that most of the SIINFEKL peptide is destroyed during processing, there may be 
other peptides within the HER2 portions of EVI that form at higher frequencies and are 
being presented more efficiently by the splenocytes.  
An advantage of this model is that it directly measures the ability of the 
presented antigen to activate cytotoxic T cells.  It is important for the desired antigen to 
not only have efficient presentation, activating more antigen presenting cells, but the 
presented antigen must also be able to activate specific cytotoxic T cells.  In that 
respect, the model is a good representation of the specific cytotoxic T cell populations 
that exist within the immune system.  It is also difficult to measure the specific antigen 
presentation in the MHC I directly on the splenocytes, as demonstrated by the lack of 
detection using the ELISA method.  A model looking at IL-2 production by splenocytes 
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presented with specific peptide antigens from HER2 may be a more effective 
representation of a HER2 specific response.  
The system has also been shown to assay the number of T cells activated, rather 
than just increasing the amount of β-gal produced by single cells.  Initial studies after 
the formation of the B3Z cells showed that increasing stimulus increased the fraction of 
cells expressing β-gal, but not the level of lacZ activity per cell  
(Kattunen & Shastri, 1991).  This gives the model physiological relevance as it mimics the 
mounting of a cytotoxic T cell response by activating a population of specific T cells. 
 In conclusion, this project has provided insight into possible mechanisms for 
increasing cross-presentation of tumor antigens.  Glycosylation was demonstrated to be 
an effective tool in increasing the cross presentation of the HER2 protein EVI.  Other 
approaches such as conjugation to GM-CSF or delivery of the protein into the cell by a 
transfection agent demonstrate the possibility of improving antigen cross-presentation.  
This project has also demonstrated the importance of finding a specific peptide to target 
within an antigenic protein in order to more efficiently stimulate cross-presentation and 
activation of cytotoxic T cells.   The observations of this project provide insights into the 
optimal antigenic conditions to consider when forming an immunogenic therapy for 
HER2 overexpressing breast cancer. 
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APPENDIX A:   
LETTER OF APPROVAL FOR THE USE OF VERTEBRATE ANIMALS IN RESEARCH FROM 
NORTHERN MICHIGAN UNIVERSITY’S DEAN OF GRADUATE STUDIES 
 
